<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1901221614
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Zavoxa
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EZETIMIBE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        118.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zavoxa&trade; is a medicine to lower increased levels of cholesterol.<br />Zavoxa&trade; lowers levels of total cholesterol, &ldquo;bad&rdquo; cholesterol<br />(LDL cholesterol), and fatty substances called triglycerides in the blood.<br />In addition, Zavoxa&trade; raises levels of &ldquo;good&rdquo; cholesterol (HDL cholesterol).<br />Ezetimibe, the active ingredient of Zavoxa&trade;, works by reducing the<br />cholesterol absorbed in your digestive tract.<br />Zavoxa&trade; adds to the cholesterol-lowering effect of statins, a group of medicines that reduce the cholesterol your body makes by itself.<br />Cholesterol is one of several fatty substances found in the bloodstream.<br />Your total cholesterol is made up mainly of LDL and HDL cholesterol.<br />LDL cholesterol is often called &ldquo;bad&rdquo; cholesterol because it can build up in<br />the walls of your arteries forming plaque. Eventually this plaque build-up<br />can lead to a narrowing of the arteries. This narrowing can slow or block<br />blood flow to vital organs such as the heart and brain. This blocking of blood<br />flow can result in a heart attack or stroke.<br />HDL cholesterol is often called &ldquo;good&rdquo; cholesterol because it helps keep the<br />bad cholesterol from building up in the arteries and protects against heart<br />disease.<br />Triglycerides are another form of fat in your blood that may increase your<br />risk for heart disease.<br />It is used for patients who cannot control their cholesterol levels by cholesterol lowering diet alone. You should stay on your cholesterol<br />lowering diet while taking this medicine.&nbsp;</p><p><strong>Zavoxa&trade; is used in addition to your cholesterol lowering diet if you<br />have:</strong><br />&bull; a raised cholesterol level in your blood (primary hypercholesterolaemia<br />[heterozygous familial and non-familial])<br />&bull; together with a statin, when your cholesterol level is not well controlled<br />with a statin alone<br />&bull; alone, when statin treatment is inappropriate or is not tolerated<br />&bull; a hereditary illness (homozygous familial hypercholesterolaemia) that<br />increases the cholesterol level in your blood. You will also be prescribed a<br />statin and may also receive other treatments.<br />&bull; a hereditary illness (homozygous sitosterolaemia, also known as<br />phytosterolaemia) that increases the levels of plant sterols in your blood.<br />If you have heart disease, Zavoxa&trade; combined with cholesterol-lowering<br />medicines called statins reduces the risk of heart attack, stroke, surgery to<br />increase heart blood flow, or hospitalisation for chest pain.<br />Zavoxa&trade; does not help you lose weight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>If you use Zavoxa&trade; together with a statin, please read the package leaflet of<br />that particular medicine.<br />Do not take Zavoxa&trade; if:<br />&bull; you are allergic (hypersensitive) to ezetimibe or any of the other ingredients<br />of this medicine (see Section 6: Contents of the pack and other information).<br />Do not take Zavoxa&trade; together with a statin if:<br />&bull; you currently have liver problems.<br />&bull; you are pregnant or breast-feeding.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Zavoxa&trade;.<br />&bull; Tell your doctor about all your medical conditions including allergies.<br />&bull; Your doctor should do a blood test before you start taking Zavoxa&trade; with a<br />statin. This is to check how well your liver is working.<br />&bull; Your doctor may also want you to have blood tests to check how well your<br />liver is working after you start taking Zavoxa&trade; with a statin.<br />If you have moderate or severe liver problems, Zavoxa&trade; is not<br />recommended.<br />The safety and efficacy of the combined use of Zavoxa&trade; and certain<br />cholesterol lowering medicines, the fibrates have not been established.<br />Children and adolescents<br />Do not give this medicine to children and adolescents (6 to 17 years of age)<br />unless prescribed by a specialist because there are limited data on safety and<br />efficacy.<br />Do not give this medicine to children less than 6 years old because there is<br />no information in this age group.<br />Other medicines and Zavoxa&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might<br />take any other medicines. In particular, tell your doctor if you are taking<br />medicine(s) with any of the following active ingredients:<br />&bull; ciclosporin (often used in organ transplant patients)<br />&bull; medicines with an active ingredient to prevent blood clots, such as<br />warfarin, phenprocoumon, acenocoumarol or fluindione (anticoagulants)<br />&bull; colestyramine (also used to lower cholesterol), because it affects the way<br />Zavoxa&trade; works<br />&bull; fibrates (also used to lower cholesterol)<br />Pregnancy and breast-feeding<br />Do not take Zavoxa&trade; with a statin if you are pregnant, are trying to get<br />pregnant or think you may be pregnant. If you get pregnant while taking<br />Zavoxa&trade; with a statin, stop taking both medicines immediately and tell your<br />doctor.<br />There is no experience from the use of Zavoxa&trade; without a statin during<br />pregnancy. Ask your doctor for advice before using Zavoxa&trade; if you are<br />pregnant.<br />Do not take Zavoxa&trade; with a statin if you are breast-feeding, because it is not<br />known if the medicines are passed into breast milk.<br />Zavoxa&trade; without a statin should not be used if you are breast-feeding. Ask<br />your doctor for advice.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />Zavoxa&trade; is not expected to interfere with your ability to drive or to use<br />machinery. However, it should be taken into account that some people may<br />get dizzy after taking Zavoxa&trade;.<br />Zavoxa&trade; contains lactose.<br />Zavoxa&trade; tablets contain a sugar called lactose. If you have been told by<br />your doctor that you have an intolerance to some sugars, contact your doctor<br />before taking this medicinal product.<br />Zavoxa&trade; tablet contains less than 1 mmol sodium (23 mg) per tablet, that is<br />to say essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you.<br />Continue taking your other cholesterol-lowering medicines unless your<br />doctor tells you to stop. You should check with your doctor or pharmacist if<br />you are not sure.<br />&bull; Before starting Zavoxa&trade;, you should be on a diet to lower your<br />cholesterol.<br />&bull; You should keep on this cholesterol lowering diet whilst taking Zavoxa&trade;.<br />The recommended dose is one Zavoxa&trade; 10 mg Tablet by mouth once a day.<br />Take Zavoxa&trade; at any time of the day. You can take it with or without food.<br />If your doctor has prescribed Zavoxa&trade; along with a statin, both medicines<br />can be taken at the same time. In this case, please read the dosage<br />instructions in the package leaflet of that particular medicine.&nbsp;</p><p>If your doctor has prescribed Zavoxa&trade; along with another medicine for<br />lowering cholesterol containing the active ingredient colestyramine or<br />any other medicine containing bile acid sequestrant, you should take<br />Zavoxa&trade; at least 2 hours before or 4 hours after taking the bile acid<br />sequestrant.<br />If you take more Zavoxa&trade; than you should<br />Please contact your doctor or pharmacist.<br />If you forget to take Zavoxa&trade;<br />Do not take a double dose to make up for a forgotten tablet, just take<br />your normal amount of Zavoxa&trade; at the usual time the next day.<br />If you stop taking Zavoxa&trade;<br />Talk to your doctor or pharmacist because your cholesterol may rise<br />again.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />The following terms are used to describe how often side effects have<br />been reported:<br />&bull; Very common (may affect more than 1 of 10 patients)<br />&bull; Common (may affect up to 1 of 10 patients)<br />&bull; Uncommon (may affect up to 1 of 100 patients)<br />&bull; Rare (may affect up to 1 of 1,000 patients)<br />&bull; Very rare<br />(may affect up to 1 of 10,000 patients, including isolated reports).<br />Contact your doctor immediately if you experience unexplained<br />muscle pain, tenderness, or weakness. This is because on rare<br />occasions, muscle problems, including muscle breakdown resulting<br />in kidney damage, can be serious and may become a potentially<br />life-threatening condition.<br />Allergic reactions, including swelling of the face, lips, tongue, and/or<br />throat that may cause difficulty in breathing or swallowing<br />(which requires treatment right away) have been reported in general use.<br />When used alone, the following side effects were reported:<br />Common: abdominal pain; diarrhoea; flatulence; feeling tired.<br />Uncommon: elevations in some laboratory blood tests of liver<br />(transaminases) or muscle (CK) function; cough; indigestion; heartburn;<br />nausea; joint pain; muscle spasms; neck pain; decreased appetite, pain,<br />chest pain, hot flush; high blood pressure.<br />Additionally, when used with a statin, the following side effects were<br />reported:<br />Common: elevations in some laboratory blood tests of liver function<br />(transaminases); headache; muscle pain, tenderness or weakness.<br />Uncommon: tingling sensation; dry mouth; itching; rash; hives; back<br />pain; muscle weakness; pain in arms and legs; unusual tiredness or<br />weakness; swelling, especially in the hands and feet.<br />When used with fenofibrate, the following common side effect was<br />reported: abdominal pain.<br />Additionally, the following side effects have been reported in general<br />use: dizziness; muscle aches; liver problems; allergic reactions including<br />rash and hives; raised red rash, sometimes with target-shaped lesions<br />(erythema multiforme); muscle pain, tenderness or weakness; muscle<br />breakdown; gallstones or inflammation of the gallbladder (which may<br />cause abdominal pain, nausea, vomiting); inflammation of the pancreas<br />often with severe abdominal pain; constipation, reduction in blood cell<br />counts, which may cause bruising/bleeding (thrombocytopaenia);<br />tingling sensation; depression: unusual tiredness or weakness; shortness<br />of breath.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This<br />includes any possible side effects not listed in this leaflet. By reporting<br />side effects you can help provide more information on the safety of this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30 &deg;C.<br />Store in the original package.<br />Do not use this medicine after the expiry date which is stated on the<br />carton and blister after &quot;EXP.&quot;<br />Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; The active substance is ezetimibe:<br />Each tablet contains 10 mg Ezetimibe.<br />&minus; The other ingredients are:<br />Lactose Monohydrate, Microcrystalline Cellulose, Croscarmellose<br />Sodium, Povidone, Sodium Lauryl Sulphate and Magnesium stearate<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White to off white, Round shaped tablets debossed with “JP’’ on one
side and “BL’’ on the other side.
Zavoxa™ 10mg tablets are available in packs of 3 blisters 10 tablets of
each.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111. Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/10/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr" style="margin-left:35.55pt; margin-right:0.1in; text-align:right; text-indent:0.2pt">زاﭬﻮﻛﺴﺎ&trade; ھﻮ دواء ﯾﺴﺘﺨﺪم ﻟﺘﻘﻠﯿﻞ ﻣﺴﺘﻮﯾﺎت اﻟﻜﻮﻟﺴﺘﺮول اﻟﻤﺮﺗﻔﻌﺔ. ﯾﻌﻤﻞ زاﭬﻮﻛﺴﺎ&trade; ﻋﻠﻰ ﺗﻘﻠﯿﻞ ﻣﺴﺘﻮى اﻟﻜﻮﻟﺴﺘﺮول اﻟﻜ&nbsp;ِﻠّﻲ واﻟﻜﻮﻟﺴﺘﺮول &quot;اﻟﻀﺎر&quot; )ﻛﻮﻟﺴﺘﺮول اﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻣﻨﺨﻔﺾ اﻟﻜﺜﺎﻓﺔ(</p><p dir="ltr" style="margin-left:35.55pt; margin-right:0in; text-align:right">واﻟﻤﻮاد اﻟﺪهنية اﻟﺘﻲ ﺗُﻌﺮف ﺑﺎﺳﻢ &quot;اﻟﺪھﻮن اﻟﺜﻼﺛﯿﺔ&quot; اﻟﻤﻮﺟﻮدة ﻓﻲ اﻟﺪم.</p><p dir="ltr" style="margin-left:35.65pt; text-align:right">ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ، ﯾﻌﻤﻞ زاﭬﻮﻛﺴﺎ&trade; ﻋﻠﻰ زﯾﺎدة ﻣﺴﺘﻮى اﻟﻜﻮﻟﺴﺘﺮول &quot;اﻟﻨﺎﻓﻊ&quot; )ﻛﻮﻟﺴﺘﺮول</p><p dir="ltr" style="margin-left:35.55pt; text-align:right">اﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻣﺮﺗﻔﻊ اﻟﻜﺜﺎﻓﺔ.(</p><p dir="ltr" style="margin-left:35.6pt; margin-right:0in; text-align:right">ﯾﻌﻤﻞ زاﭬﻮﻛﺴﺎ&trade; وھﻮ اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻲ زاﭬﻮﻛﺴﺎ&trade; ﻋﻠﻰ ﺗﻘﻠﯿﻞ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول اﻟﺬي ﯾﺘﻢ</p><p dir="ltr" style="text-align:right">اﻣﺘﺼﺎﺻﮫ داﺧﻞ اﻟﺠﮭﺎز اﻟﮭﻀﻤﻲ.</p><p dir="ltr" style="margin-left:35.55pt; margin-right:0in; text-align:right">ﯾﻀﯿﻒ زاﭬﻮﻛﺴﺎ&trade; إﻟﻰ ﺗﺄﺛﯿﺮ ﺗﻘﻠﯿﻞ اﻟﻜﻮﻟﺴﺘﺮول اﻟﺬي ﯾﻘﻮم ﺑﮫ اﻟﺴﺘﺎﺗﯿﻨﺎت، وھﻮ ﻣﻦ ﻣﺠﻤﻮﻋﺔ ﻣﻦ</p><p dir="ltr" style="margin-left:35.6pt; margin-right:8.45pt; text-align:right; text-indent:63.8pt">اﻷدوﯾﺔ اﻟﺘﻲ ﺗﻘﻠﻞ ﻣﺴﺘﻮى اﻟﻜﻮﻟﺴﺘﺮول اﻟﺬي ﯾﻨﺘﺠﮫ اﻟﺠﺴﻢ ﺑﻨﻔﺴﮫ. ﯾﻌﺪ اﻟﻜﻮﻟﺴﺘﺮول أﺣﺪ اﻟﻤﻮاد اﻟﺪھﻨﯿﺔ اﻟﻤﺘﻌﺪدة اﻟﻤﻮﺟﻮدة ﻓﻲ ﻣﺠﺮى اﻟﺪم. ﯾﺘﻜﻮن اﻟﻜﻮﻟﺴﺘﺮول اﻟﻜ&nbsp;ِﻠّﻲ ﺑﺸﻜﻞ أﺳﺎﺳﻲ ﻣﻦ ﻛﻮﻟﺴﺘﺮول اﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻣﻨﺨﻔﺾ اﻟﻜﺜﺎﻓﺔ وﻛﻮﻟﺴﺘﺮول اﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻣﺮﺗﻔﻊ</p><p dir="ltr" style="text-align:right">اﻟﻜﺜﺎﻓﺔ.</p><p dir="ltr" style="margin-left:35.5pt; margin-right:10.55pt; text-align:right; text-indent:0.2pt">ﻋﺎدةً&nbsp;ﻣﺎ ﯾُﺴﻤﻰ ﻛﻮﻟﺴﺘﺮول اﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻣﻨﺨﻔﺾ اﻟﻜﺜﺎﻓﺔ ﺑﺎﺳﻢ اﻟﻜﻮﻟﺴﺘﺮول &quot;اﻟﻀﺎر&quot;؛ ﺣﯿﺚ أﻧﮫ اﻟﺪم ﯾﺘﺮاﻛﻢ ﻋﻠﻰ ﺟﺪران اﻟﺸﺮاﯾﯿﻦ ﻣﻜﻮﻧﻨًﺎ ﺗﺮﺳﺒﺎت ﺑﺪاﺧﻠﮭﺎ. وﻓﻲ اﻟﻨﮭﺎﯾﺔ، ﯾُﻤﻜﻦ أن ﯾﺆدي ﺗﺮاﻛﻢ ھﺬه أو اﻟﺘﺮﺳﺒﺎت إﻟﻰ ﺗﻀﯿﻖ اﻟﺸﺮاﯾﯿﻦ. وﺑﺎﻟﺘﺎﻟﻲ ﻓﺈن ﺿﯿﱡﻖ اﻟﺸﺮاﯾﯿﻦ ﻗﺪ ﯾﺘﺴﺒﺐ ﻓﻲ إﺑﻄﺎء أو ﻣﻨﻊ ﺗﺪﻓﻖ إﻟﻰ اﻷﻋﻀﺎء اﻟﺤﯿﻮﯾﺔ ﻣﺜﻞ اﻟﻘﻠﺐ واﻟﺪﻣﺎغ. وﻗﺪ ﯾﺆدي ﻣﻨﻊ ﺗﺪﻓﻖ اﻟﺪم إﻟﻰ اﻹﺻﺎﺑﺔ ﺑﺄزﻣﺔ ﻗﻠﺒﯿﺔ</p><p dir="ltr" style="text-align:right">ﺳﻜﺘﺔ دﻣﺎﻏﯿﺔ.</p><p dir="ltr" style="text-align:right">ﯾُﺴﻤﻰ ﻛﻮﻟﺴﺘﺮول اﻟﺒﺮوﺗﯿﻦ اﻟﺪھﻨﻲ ﻣﺮﺗﻔﻊ اﻟﻜﺜﺎﻓﺔ ﻋﺎدة ﺑﺎﺳﻢ اﻟﻜﻮﻟﺴﺘﺮول &quot;اﻟﻨﺎﻓﻊ&quot;؛ ﻷﻧﮫ ﯾُﺴﺎﻋﺪ ﻋﻠﻰ</p><p dir="ltr" style="margin-left:35.5pt; margin-right:13.6pt; text-align:right; text-indent:35.65pt">ﻣﻨﻊ اﻟﻜﻮﻟﺴﺘﺮول اﻟﻀﺎر ﻣﻦ اﻟﺘﺮاﻛﻢ ﻓﻲ اﻟﺸﺮاﯾﯿﻦ وﯾﺤﻤﻲ ﻣﻦ أﻣﺮاض اﻟﻘﻠﺐ. ﺗُﻌَﺪ اﻟﺪھﻮن اﻟﺜﻼﺛﯿﺔ أﺣﺪ أﻧﻮاع اﻟﺪھﻮن اﻟﻤﻮﺟﻮدة ﺑﺎﻟﺪم واﻟﺘﻲ ﻗﺪ ﺗﺰﯾﺪ ﻣﻦ ﺧﻄﺮ اﻹﺻﺎﺑﺔ ﺑﺄﻣﺮاض</p><p dir="ltr" style="text-align:right">اﻟﻘلب</p><p dir="ltr" style="margin-left:35.55pt; margin-right:12.3pt; text-align:right; text-indent:-5.1pt">ﯾﺴﺘﺨﺪم ھﺬا اﻟﺪواء ﻓﻲ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﻻ ﯾﻤﻠﻜﻮن اﻟﻘﺪرة ﻋﻠﻰ اﻟﺘﺤﻜﻢ ﻓﻲ ﻧﺴﺒﺔ ﻣﺴﺘﻮﯾﺎت اﻟﻜﻮﻟﺴﺘﺮول ﻋﻦ طﺮﯾﻖ اﺗﺒﺎع ﻧﻈﺎم ﻏﺬاﺋﻲ ﻓﻘﻂ ﻓﻲ ﺗﻘﻠﯿﻞ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول. ﯾﺠﺐ ﻋﻠﯿﻚ اﺗﺒﺎع ﻧﻈﺎم ﻏﺬاﺋﻲ ﯾﻘﻠﻞ</p><p dir="ltr" style="margin-left:35.55pt; margin-right:0in; text-align:right">ﻣﻦ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول ﺑﺠﺎﻧﺐ ﺗﻨﺎول ھﺬا اﻟﺪواء.</p><p dir="ltr" style="text-align:right">ﯾُﺴﺘﺨﺪم زاﭬﻮﻛﺴﺎ&trade; ﺑﺠﺎﻧﺐ اﺗﺒﺎع ﻧﻈﺎم ﻏﺬاﺋﻲ ﯾﻘﻠﻞ ﻣﻦ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول ﻓﻲ اﻟﺤﺎﻻت اﻟﺘﺎﻟﯿﺔ:</p><p dir="ltr" style="margin-left:35.45pt; margin-right:0in; text-align:right">&bull; ﯾُﺴﺘﺨﺪم ﻋﻨﺪ ارﺗﻔﺎع ﻣﺴﺘﻮى اﻟﻜﻮﻟﺴﺘﺮول ﻓﻲ اﻟﺪﱠم )ﻓﺮط ﻛﻮﻟﺴﺘﺮول اﻟﺪﱠم اﻷوﻟﻲ( ]ﻣﺘﺒﺎﯾﻦ اﻟﺠﯿﻨﺎت</p><p dir="ltr" style="margin-left:35.45pt; margin-right:11.1pt; text-align:right; text-indent:131.8pt">اﻟﻌﺎﺋﻠﻲ أو ﻏﯿﺮ اﻟﻌﺎﺋﻠﻲ([ &bull; ﯾُﺴﺘﺨﺪم ھﺬا اﻟﺪواء ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ اﻟﺴﺘﺎﺗﯿﻦ، ﻓﻲ ﺣﺎﻟﺔ ﻋﺪم اﻧﺘﻈﺎم ﻣﺴﺘﻮى اﻟﻜﻮﻟﺴﺘﺮول ﻓﻲ اﻟﺪم ﻋﻨﺪ</p><p dir="ltr" style="margin-left:35.45pt; margin-right:18.3pt; text-align:right; text-indent:131.8pt">اﺳﺘﺨﺪام ﺳﺘﺎﺗﯿﻦ ﻓﻘﻂ. &bull; ﯾُﺴﺘﺨﺪم ھﺬا اﻟﺪواء ﻣﻨﻔﺮدًا ﻋﻨﺪﻣﺎ ﯾﻜﻮن اﻟﻌﻼج ﺑﺄدوﯾﺔ اﻟﺴﺘﺎﺗﯿﻦ ﻏﯿﺮ ﻣﻼﺋﻢ ﻟﺤﺎﻟﺘﻚ أو ﻻ ﯾﻤﻜﻦ</p><p dir="ltr" style="margin-left:35.45pt; margin-right:11.4pt; text-align:right; text-indent:164.35pt">ﺗﺤﻤﻠﮫ. &bull; ﯾُﺴﺘﺨﺪم ھﺬا اﻟﺪواء ﻟﻌﻼج ﻣﺮض وراﺛﻲ )ﻓﺮط ﻛﻮﻟﺴﺘﺮول اﻟﺪم اﻟﻌﺎﺋﻠﻲ ﻣﺘﺠﺎﻧﺲ اﻟﺠﯿﻨﺎت( واﻟﺬي ﯾﻌﻤﻞ ﻋﻠﻰ زﯾﺎدة ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول ﻓﻲ اﻟﺪم. ﺳﯿﺘﻢ أﯾﻀﺎ وﺻﻒ أدوﯾﺔ اﻟﺴﺘﺎﺗﯿﻦ ﻟﻚ وﻗﺪ ﺗﺘﻠﻘﻰ أدوﯾﺔ</p><p dir="ltr" style="margin-left:35.45pt; margin-right:10.2pt; text-align:right; text-indent:164.85pt">أﺧﺮى. &bull; ﯾﺴﺘﺨﺪم ھﺬا اﻟﺪواء ﻟﻌﻼج ﻣﺮض وراﺛﻲ )ﻓﺮط ﺳﯿﺘﻮﺳﺘﯿﺮول ﻓﻲ اﻟﺪم ﻣﺘﺠﺎﻧﺲ اﻟﺠﯿﻨﺎت اﻟﻤﻌﺮوف</p><p dir="ltr" style="margin-left:35.45pt; margin-right:0in; text-align:right">أﯾﻀﺎ ﺑﺎﺳﻢ ﻓﺮط ﻓﯿﺘﻮﺳﺘﯿﺮول ﺑﺎﻟﺪم( وھﻮ ﻣﺮض ﯾﺘﺴﺒﺐ ﻓﻲ زﯾﺎدة ﻣﺴﺘﻮى ﺳﺘﯿﺮول اﻟﻨﺒﺎﺗﻲ ﻓﻲ اﻟﺪم.</p><p dir="ltr" style="margin-left:35.55pt; margin-right:10.3pt; text-align:right; text-indent:7.1pt">إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ أﻣﺮاض ﺑﺎﻟﻘﻠﺐ، ﻓﺈن ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ اﻷدوﯾﺔ اﻟﺘﻲ ﺗﻘﻠﻞ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول وﺗﺴﻤﻰ ﺑﺄدوﯾﺔ اﻟﺴﺘﺎﺗﯿﻦ اﻟﺘﻲ ﺗﺤﺪ ﻣﻦ ﻣﺨﺎطﺮ اﻹﺻﺎﺑﺔ ﺑﺄزﻣﺔ ﻗﻠﺒﯿﺔ أو ﺳﻜﺘﺔ دﻣﺎﻏﯿﺔ أو</p><p dir="ltr" style="text-align:right">اﻟﺤﺎﺟﺔ ﻹﺟﺮاء ﻋﻤﻠﯿﺔ ﺟﺮاﺣﯿﺔ ﻟﺰﯾﺎدة ﺗﺪﻓﻖ اﻟﺪم ﺑﺎﻟﻘﻠﺐ أو دﺧﻮل اﻟﻤﺴﺘﺸﻔﻰ ﻟﻌﻼج آﻟﻢ اﻟﺼﺪر.</p><p dir="ltr" style="text-align:right">ﻻ ﯾﺴﺎﻋﺪك زاﭬﻮﻛﺴﺎ&trade; ﻋﻠﻰ ﻓﻘﺪان اﻟﻮزن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:35.55pt; text-align:justify">ﯾﺮﺟﻰ ﻗﺮاءة ﻧﺸﺮة اﻟﻌﺒﻮة اﻟﺨﺎﺻﺔ ﺑﮭﺬا اﻟﺪواء، إذا ﺗﻨﺎوﻟﺖ زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ ﺳﺘﺎﺗﯿﻦ.</p><p style="text-align:justify">ﯾﺤﻈﺮ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﻓﻲ اﻟﺤﺎﻻت اﻟﺘﱠﺎﻟﯿﺔ:</p><p style="margin-right:35.55pt; text-align:justify">&bull; إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ ﺣﺴﺎﺳﯿﺔ )ﻓﺮط ﺣﺴﺎﺳﯿﺔ( ﺗﺠﺎه إﯾﺰﯾﺘﯿﻤﺎﯾﺐ أو أي ﻣﻜﻮن ﻣﻦ اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى</p><p style="margin-right:35.45pt; text-align:justify">اﻟﺪاﺧﻠﺔ ﻓﻲ ﺗﺮﻛﯿﺐ ھﺬا اﻟﺪواء )اﻧﻈﺮ اﻟﻘﺴﻢ رﻗﻢ ٦: ﻣﺤﺘﻮﯾﺎت اﻟﻌﺒﻮة وﻣﻌﻠﻮﻣﺎت أﺧﺮى.(</p><p style="text-align:justify">ﯾﺤﻈﺮ ﺗﺘﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ ﺳﺘﺎﺗﯿﻦ ﻓﻲ اﻟﺤﺎﻻت اﻟﺘﺎﻟﯿﺔ:</p><p style="margin-left:0in; margin-right:35.55pt; text-align:justify">&bull; إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﺣﺎﻟﯿًﺎ ﻣﻦ ﻣﺸﺎﻛﻞ ﺑﺎﻟﻜﺒﺪ.</p><p style="text-align:justify">&bull; إذا ﻛﻨﺖ ﺣﺎﻣﻼ أو ﺗﻤﺎرﺳﯿﻦ اﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ.</p><p style="text-align:justify">ﺗﺤﺬﯾﺮات واﺣﺘﯿﺎطﺎت</p><p style="margin-right:35.6pt; text-align:justify">اﺳﺘﺸﺮ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ أو اﻟﺼﯿﺪﻟﻲ اﻟﺨﺎص ﺑﻚ ﻗﺒﻞ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﻓﻲ اﻟﺤﺎﻻت اﻟﺘﺎﻟﯿﺔ:</p><p style="margin-left:7.45pt; text-align:justify; text-indent:9.45pt">&bull; أﺧﺒﺮ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ ﻋﻦ ﺟﻤﯿﻊ اﻟﻤﺸﺎﻛﻞ اﻟﺼﺤﯿﺔ اﻟﺘﻲ ﺗﻌﺎﻧﻲ ﻣﻨﮭﺎ ﺑﻤﺎ ﻓﻲ ذﻟﻚ اﻟﺤﺴﺎﺳﯿﺔ. &bull; ﯾﺘﻌﯿﻦ ﻋﻠﻰ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ اﺟﺮاء ﻓﺤﻮﺻﺎت ﻟﻠﺪم ﻗﺒﻞ اﻟﺒﺪء ﻓﻲ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ</p><p style="margin-left:15.05pt; margin-right:35.5pt; text-align:justify; text-indent:84.85pt">ﺳﺘﺎﺗﯿﻦ، وذﻟﻚ ﻟﻠﺘﺤﻘﻖ ﻣﻦ ﻣﺪى ﻛﻔﺎءة ﻋﻤﻞ اﻟﻜﺒﺪ. &bull; ﻛﻤﺎ ﻗﺪ ﯾﺮﻏﺐ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ أﯾﻀﺎ ﻓﻲ إﺟﺮاء ﻓﺤﻮﺻﺎت ﻟﻠﺪم ﻟﻠﺘﺤﻘﻖ ﻣﻦ ﻣﺪى ﻛﻔﺎءة ﻋﻤﻞ</p><p style="text-align:justify">اﻟﻜﺒﺪ ﺑﻌﺪ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ ﺳﺘﺎﺗﯿﻦ.</p><p style="margin-left:7.8pt; margin-right:35.5pt; text-align:justify; text-indent:11.2pt">إذا ﻛﺎن ﺗﻌﺎﻧﻲ ﻣﻦ ﻣﺸﺎﻛﻞ ﺑﺎﻟﻜﺒﺪ ﻣﺘﻮﺳﻄﺔ أو ﺷﺪﯾﺪة اﻟﺨﻄﻮرة، ﻓﻼ ﯾُﻮﺻﻰ ﺑﺘﻨﺎول زاﭬﻮﻛﺴﺎ.&trade; ﻟﻢ ﯾﺘﻢ اﻟﺘﱠﺤﻘﻖ ﻣﻦ أﻣﺎن وﻓﻌﺎﻟﯿﺔ اﺳﺘﺨﺪام زاﭬﻮﻛﺴﺎ&trade; وﺑﻌﺾ اﻷدوﯾﺔ اﻟﺘﻲ ﺗﻘﻠﻞ ﻣﻦ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول</p><p style="text-align:justify">واﻟﻔﯿﺒﺮات.</p><p style="margin-left:10.6pt; margin-right:35.45pt; text-align:justify; text-indent:89.85pt"><strong>اﻻﺳﺘﺨﺪام ﻓﻲ اﻟﻤﺮﺿﻰ ﻣﻦ اﻷطﻔﺎل واﻟﻤﺮاھﻘﯿﻦ </strong>ﯾﺤﻈﺮ اﺳﺘﺨﺪام ھﺬا اﻟﺪواء ﻓﻲ اﻟﻤﺮﺿﻰ ﻣﻦ اﻷطﻔﺎل واﻟﻤﺮاھﻘﯿﻦ اﻟﺬﯾﻦ ﺗﺘﺮاوح أﻋﻤﺎرھﻢ ﻣﻦ )٦ إﻟﻰ ۷۱ ﻋﺎﻣﺎ( ﻣﺎ ﻟﻢ ﯾﺼﻔﮫ أﺣﺪ اﻟﻤﺘﺨﺼﺼﯿﻦ وذﻟﻚ ﻟﻌﺪم ﺗﻮاﻓﺮ ﺑﯿﺎﻧﺎت ﻛﺎﻓﯿﺔ ﺣﻮل أﻣﺎن وﻓﻌﺎﻟﯿﺔ</p><p style="margin-left:16.05pt; margin-right:35.45pt; text-align:justify; text-indent:101.25pt">ﺗﻨﺎول ھﺬا اﻟﺪواء ﻓﻲ ھﺬه اﻟﻔﺌﺔ اﻟﻌﻤﺮﯾﺔ. ﯾﺤﻈﺮ إﻋﻄﺎء ھﺬا اﻟﺪواء ﻟﻸطﻔﺎل اﻟﺬﯾﻦ ﺗﻘﻞ أﻋﻤﺎرھﻢ ﻋﻦ ٦ ﺳﻨﻮات وذﻟﻚ ﻟﻌﺪم ﺗﻮاﻓﺮ ﻣﻌﻠﻮﻣﺎت</p><p style="margin-left:11.7pt; margin-right:35.5pt; text-align:justify; text-indent:104.05pt">ﺑﺸﺄن اﺳﺘﺨﺪاﻣه ﻓﻲ هﺬه اﻟﻔﺌﺔ اﻟﻌﻤﺮﯾﺔ.</p><p style="margin-left:11.7pt; margin-right:35.5pt; text-align:justify; text-indent:104.05pt"><strong>ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﻣﻊ اﻷدوﯾﺔ اﻷﺧﺮى: </strong></p><p style="margin-left:11.7pt; margin-right:35.5pt; text-align:justify; text-indent:104.05pt">ﯾُﺮﺟﻰ إﺑﻼغ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ أو اﻟﺼﯿﺪﻟﻲ اﻟﺨﺎص ﺑﻚ، إذا ﻛﻨﺖ ﺗﺘﻨﺎول أو ﺗﻨﺎوﻟﺖ ﻣﺆﺧﺮا أو ﻗﺪ ﺗﺘﻨﺎول أﯾﱠﺔ أدوﯾﺔ أﺧﺮى. وﻋﻠﻰ وﺟﮫ اﻟﺨﺼﻮص، أﺧﺒﺮ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ إذا ﻛﻨﺖ ﺗﺘﻨﺎول دواء</p><p style="margin-left:0in; margin-right:35.55pt; text-align:justify">/أدوﯾﺔ ﺗﺤﺘﻮي ﻋﻠﻰ أي ﻣﻦ اﻟﻤﻮاد اﻟﻔﻌﺎﻟﺔ اﻟﺘﺎﻟﯿﺔ:</p><p style="margin-left:9.35pt; margin-right:35.45pt; text-align:justify; text-indent:11.75pt">&bull; ﺳﯿﻜﻠﻮﺳﺒﻮرﯾﻦ )دواء ﯾُﺴﺘﺨﺪَم ﻋﺎدةً ﻓﻲ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﺠﺮون ﻋﻤﻠﯿﺎت زراﻋﺔ اﻷﻋﻀﺎء.( &bull; اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ ﻣﺎدة ﻓﻌﺎﻟﺔ ﻟﻤﻨﻊ ﺗﺨﺜﺮ )ﺗﺠﻠﻂ( اﻟﺪﱠم، ﻣﺜﻞ: وارﻓﺎرﯾﻦ أو ﻓﯿﻨﺒﺮوﻛﻮﻣﻮن أو</p><p style="margin-left:30.8pt; margin-right:35.45pt; text-align:justify; text-indent:68.55pt">أﺳﯿﻨُﻮﻛﻮﻣﺎرول أو ﻓﻠﻮﯾﻨﺪﯾﻮن )ﻣﻀﺎدات اﻟﺘﱠﺠﻠﻂ.( &bull; ﻛﻮﻟﯿﺴﺘﯿﺮاﻣﯿﻦ )دواء ﯾﺴﺘﺨﺪم أﯾﻀﺎ ﻟﺘﻘﻠﯿﻞ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول(؛ ﺣﯿﺚ ﯾُﺆﺛﺮ ﻋﻠﻰ ﻓﺎﻋﻠﯿﺔ</p><p style="margin-left:0in; margin-right:35.45pt; text-align:justify">زاﭬﻮﻛﺴﺎ.&trade;</p><p style="text-align:justify">&bull; اﻟﻔﯿﺒﺮات )أدوﯾﺔ ﺗﺴﺘﺨﺪم أﯾﻀﺎ ﻟﺘﻘﻠﯿﻞ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول.(</p><p style="margin-left:11.25pt; margin-right:35.5pt; text-align:justify; text-indent:127.25pt"><strong>اﻟﺤﻤﻞ واﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ </strong>إذا ﻛﻨﺖ ﺣﺎﻣﻼ أو ﺗﺤﺎوﻟﯿﻦ اﻟﺤﻤﻞ أو ﺗﻌﺘﻘﺪﯾﻦ أﻧﻚ ﺣﺎﻣﻼً، ﯾﺤﻈﺮ ﻋﻠﯿﻚ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ ﺳﺘﺎﺗﯿﻦ. إذا أﺻﺒﺤﺖ ﺣﺎﻣﻼ أﺛﻨﺎء ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ ﺳﺘﺎﺗﯿﻦ، ﯾﺠﺐ ﻋﻠﯿﻚ اﻟﺘﻮﻗﻒ</p><p style="margin-left:14.7pt; margin-right:35.45pt; text-align:justify; text-indent:56.15pt">ﻋﻦ ﺗﻨﺎول ﻛﻼ اﻟﺪواﺋﯿﯿﻦ ﻋﻠﻰ اﻟﻔﻮر وأﺧﺒﺮي اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ. ﻻ ﺗﺘﻮاﻓﺮ ﺗﺠﺎرب ﻛﺎﻓﯿﺔ ﺣﻮل اﺳﺘﺨﺪام زاﭬﻮﻛﺴﺎ&trade; ﻣﻨﻔﺮدًا ﺑﺪون ﺳﺘﺎﺗﯿﻦ أﺛﻨﺎء ﻓﺘﺮة اﻟﺤﻤﻞ. ﯾُﺮﺟﻰ</p><p style="text-align:justify">اﺳﺘﺸﺎرة اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ ﻟﻠﺤﺼﻮل ﻋﻠﻰ اﻟﻨﺼﯿﺤﺔ ﻗﺒﻞ اﺳﺘﺨﺪام زاﭬﻮﻛﺴﺎ&trade; إذا ﻛﻨﺖ ﺣﺎﻣﻼ.</p><p style="margin-left:0in; margin-right:35.45pt; text-align:justify">ﯾﺤﻈﺮ ﻋﻠﯿﻚ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ ﺳﺘﺎﺗﯿﻦ إذا ﻛﻨﺖ ﺗﻤﺎرﺳﯿﻦ اﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ، ﻷﻧﮫ ﻣﻦ</p><p style="margin-right:35.45pt; text-align:justify">ﻏﯿﺮ اﻟﻤﻌﺮوف ﻣﺎ إذا ﻛﺎﻧﺖ ھﺬه اﻷدوﯾﺔ ﺗﻤﺮ إﻟﻰ ﻟﺒﻦ اﻷم أم ﻻ.</p><p style="margin-right:35.45pt; text-align:justify">ﯾﺤﻈﺮ ﻋﻠﯿﻚ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﻣﻨﻔﺮدًا ﺑﺪون ﺳﺘﺎﺗﯿﻦ إذا ﻛﻨﺖ ﺗﻤﺎرﺳﯿﻦ اﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ.</p><p style="margin-right:35.45pt; text-align:justify">اﺳﺘﺸﯿﺮي اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ ﻟﻠﺤﺼﻮل ﻋﻠﻰ اﻟﻨﺼﯿﺤﺔ ﺣﻮل ھﺬا اﻷﻣﺮ.</p><p style="margin-right:35.45pt; text-align:justify">اﺳﺘﺸﯿﺮي اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ أو اﻟﺼﯿﺪﻟﻲ اﻟﺨﺎص ﺑﻚ ﻗﺒﻞ ﺗﻨﺎول أي دواء.</p><p style="text-align:justify">اﻟﻘﯿﺎدة واﺳﺘﺨﺪام اﻵﻻت</p><p style="margin-left:0in; margin-right:35.45pt; text-align:justify">ﻣﻦ ﻏﯿﺮ اﻟﻤﺤﺘﻤﻞ أن ﯾُﺆﺛﺮ زاﭬﻮﻛﺴﺎ&trade; ﻋﻠﻰ ﻗﺪرﺗﻚ ﻋﻠﻰ ﻗﯿﺎدة اﻟﺴﯿﺎرات أو اﺳﺘﺨﺪام اﻵﻻت. وﻣﻊ</p><p style="text-align:justify">ذﻟﻚ، ﯾﺠﺐ اﻟﻮﺿﻊ ﻓﻲ اﻻﻋﺘﺒﺎر أﻧﮫ ﻗﺪ ﯾﺼﺎب ﺑﻌﺾ اﻷﺷﺨﺎص ﺑﺪوﺧﺔ ﺑﻌﺪ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ.&trade;</p><p style="margin-left:12.2pt; margin-right:35.45pt; text-align:justify; text-indent:112.3pt">ﯾﺤﺘﻮي زاﭬﻮﻛﺴﺎ&trade; ﻋﻠﻰ اﻟﻼﻛﺘﻮز: ﯾﺤﺘﻮي زاﭬﻮﻛﺴﺎ&trade; أﻗﺮاص ﻋﻠﻰ ﺳﻜﺮ ﯾُﻌﺮف ﺑﺎﺳﻢ اﻟﻼﻛﺘﻮز. إذا أﺧﺒﺮك اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ ﺑﺄﻧﻚ</p><p style="text-align:justify">ﻟﯿﺲ ﻟﺪﯾﻚ اﻟﻘﺪرة ﻋﻠﻰ ﺗﺤﻤﻞ ﺑﻌﺾ أﻧﻮاع اﻟﺴﻜﺮﯾﺎت، ﻓﺎﺳﺘﺸﺮه ﻗﺒﻞ ﺗﻨﺎول ھﺬا اﻟﻤﻨﺘﺞ اﻟﺪواﺋﻲ.</p><p style="margin-left:0in; margin-right:35.45pt; text-align:justify">ﺗﺤﺘﻮي زاﭬﻮﻛﺴﺎ&trade; أﻗﺮاص ﻋﻠﻰ أﻗﻞ ﻣﻦ ۱ ﻣﻠﻠﯿﻤﻮل ﺻﻮدﯾﻮم )۳۲ ﻣﻠﺠﻢ( ﻟﻜﻞ ﻗﺮص ، وھﺬا ﯾﻌﻨﻲ</p><p style="text-align:justify">ﺑﺸﻜﻞ أﺳﺎﺳﻲ &quot;ﺧﺎل ﻣﻦ اﻟﺼﻮدﯾﻮم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:14.8pt; margin-right:35.5pt; text-align:right; text-indent:-2.0pt">ﺗﻨﺎول داﺋﻤﺎ ھﺬا اﻟﺪواء ﺑﺎﻟﻀﺒﻂ ﻛﻤﺎ أﺧﺒﺮك اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ. اﺳﺘﻤﺮ ﻓﻲ ﺗﻨﺎول اﻷدوﯾﺔ اﻷﺧﺮى اﻟﺘﻲ ﺗﻘﻠﻞ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول ﻣﺎ ﻟﻢ ﯾﺨﺒﺮك اﻟﻄﺒﯿﺐ ﺑﺎﻟﺘﻮﻗﻒ ﻋﻦ ﺗﻨﺎوﻟﮭﺎ. ﯾﺘﻌﯿﻦ ﻋﻠﯿﻚ اﻟﺮﺟﻮع إﻟﻰ</p><p dir="RTL" style="margin-left:0in; margin-right:35.55pt; text-align:right">اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ أو اﻟﺼﯿﺪﻟﻲ اﻟﺨﺎص ﺑﻚ إذا ﻟﻢ ﺗﻜﻦ ﻣﺘﺄﻛﺪًا ﻣﻦ ﻛﯿﻔﯿﺔ اﻟﺘﻨﺎول.</p><p dir="RTL" style="margin-right:35.6pt; text-align:right">&bull; ﯾﺠﺐ ﻋﻠﯿﻚ اﺗﺒﺎع ﻧﻈﺎم ﻏﺬاﺋﻲ ﻟﺘﻘﻠﯿﻞ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول ﻗﺒﻞ اﻟﺒﺪء ﻓﻲ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ.&trade;</p><p dir="RTL" style="margin-right:35.55pt; text-align:right">&bull; ﯾﺠﺐ ﻋﻠﯿﻚ اﻟﻤﻮاظﺒﺔ ﻋﻠﻰ اﻟﻨﻈﺎم اﻟﻐﺬاﺋﻲ اﻟﻤﺘﺒﻊ ﻟﺘﻘﻠﯿﻞ ﻧﺴﺒﺔ ﻟﻠﻜﻮﻟﺴﺘﺮول أﺛﻨﺎء ﺗﻨﺎول زاﭬﻮﻛﺴﺎ.&trade;</p><p dir="RTL" style="margin-left:0in; margin-right:35.55pt; text-align:right">اﻟﺠﺮﻋﺔ اﻟﻤﻮﺻﻲ ﺑﮭﺎ ﻣﻦ زاﭬﻮﻛﺴﺎ&trade; ھﻲ ﻗﺮص ۰۱ ﻣﻠﺠﻢ ﯾﺘﻢ ﺗﻨﺎوﻟﮫ ﻋﻦ طﺮﯾﻖ اﻟﻔﻢ ﻣﺮة واﺣﺪة</p><p dir="RTL" style="text-align:right">ﯾﻮميا</p><p dir="RTL" style="margin-left:7.1pt; margin-right:35.5pt; text-align:right; text-indent:43.6pt">ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﻓﻲ أي وﻗﺖ ﻣﻦ اﻟﯿﻮم. ﯾﻤﻜﻨﻚ ﺗﻨﺎوﻟﮫ ﻣﻊ اﻟﻄﻌﺎم أو ﺑﺪوﻧﮫ. إذا وﺻﻒ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ ﺳﺘﺎﺗﯿﻦ، ﯾﻤﻜﻨﻚ ﺗﻨﺎول ﻛﻼ اﻟﺪواﺋﯿﯿﻦ ﻓﻲ ﻧﻔﺲ</p><p dir="RTL" style="text-align:right">اﻟﻮﻗﺖ. وﻓﻲ ھﺬه اﻟﺤﺎﻟﺔ، ﯾُﺮﺟﻰ ﻗﺮاءة ﺗﻌﻠﯿﻤﺎت اﻟﺠﺮﻋﺔ ﻓﻲ ﻧﺸﺮة اﻟﻌﺒﻮة اﻟﺨﺎﺻﺔ ﺑﮭﺬا اﻟﺪﱠواء.</p><p dir="RTL" style="margin-left:15.2pt; margin-right:35.5pt; text-align:right; text-indent:.35pt">إذا وﺻﻒ اﻟﻄﺒﯿﺐ اﻟﻤﻌﺎﻟﺞ ﻟﻚ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ دواء آﺧﺮ ﯾﻘﻠﻞ ﻧﺴﺒﺔ اﻟﻜﻮﻟﺴﺘﺮول وﯾﺤﺘﻮي ﻋﻠﻰ اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ﻛﻮﻟﯿﺴﺘﯿﺮاﻣﯿﻦ أو أي دواء آﺧﺮ ﯾﺤﺘﻮي ﻋﻠﻰ ﻣﻨﺤﯿﺎت اﻷﺣﻤﺎض اﻟﺼﻔﺮاوﯾﺔ )أﺣﻤﺎض اﻟﻤﺮارة(، ﯾﺠﺐ ﻋﻠﯿﻚ ﺗﻨﺎول زاﭬﻮﻛﺴﺎ&trade; ﻗﺒﻞ ﺳﺎﻋﺘﯿﻦ ﻋﻠﻰ اﻷﻗﻞ أو أرﺑﻌﺔ ﺳﺎﻋﺎت ﺑﻌﺪ ﺗﻨﺎول اﻟﺪواء اﻟﺬي ﯾﺤﺘﻮي ﻋﻠﻰ ﻣﻨﺤﯿﺎت اﻷﺣﻤﺎض اﻟﺼﻔﺮاوﯾﺔ</p><p>إذا نسيت تناول زافوكسا &trade;</p><p>لا تتناول جرعة مضاعفة لتعويض جرعة منسية, تناول فقط الجرعة الثانية من عقار زافوكسا</p><p>إذا توقفت عن تناول زافوكسا &trade;</p><p>تحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك؛قد يرتفع مستوى الكوليستيرول مرة أخرى.</p><p>&nbsp;</p><p>إذا كانت لديك أية أسئلة إضافية حول إستخدام هذا الدواء,فاستشر الطبيب المعالج لك أو الصيدلي الخاص بك<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبب هذا الدَّواء آثارًا جانبية، مثله مثل كافة الأدوية، على الرَّغم من عدم حدوث هذا لجميع<br />المرضى.</p><p>تستخدم المصطلحات التالیة لوصف معدل الإبلاغ عن حدوث الآثار الجانبية:<br />ا (قد تُؤثر على أكثر من مريض واحد من بين كل ۱۰ مرضى).&nbsp; &bull; آثار جانبية شائعة جدًا<br />&bull; آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰ مرضى).<br />&bull; آثار جانبية غير شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بين كل ۱۰۰ مریض).<br />&bull; آثار جانبية نادرة (قد تؤثر على ما يصل إلى مريض واحد من بين كل ۱,۰۰۰ مريض).<br />ا (قد تؤثر على ما یصل إلى مريض واحد من كل ۱۰,۰۰۰ مريض، 􀌒 &bull; آثار جانبية نادرة جدًا و يشمل ذلك عملیات الإبلاغ المنفصلة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدًا عن متناول و مرأى الأطفال.<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ &deg; درجة مئوية.<br />يحفظ داخل العبوة الأصلية.<br />لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العلبة الكرتونية و شريط بعد كلمة<br />.&quot;.EXP&quot;<br />تجنب التخلص من الأدوية عن طريق إلقائها عبر مياه الصرف الصحي أو مع المخلفات<br />المنزلية. استشر الصيدلي الخاص بك حول كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها.<br />ستساعد هذه الإجراءات على حماية البيئة والحفاظ عليها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&trade; ما هي محتويات زاڤوكسا<br />- المادة الفعَّالة ھي إزيتامايب<br />يحتوي كل قرص على ۱۰ ملجم من إيزيتيماب.<br />- المكونات الأخرى هي:<br />لاكتوز أحادي الهيدرات، سليلوز دقيق التَّبلور، كروسكارميلوز الصوديوم، بوفيدون، لوريل<br />سلفات الصوديوم و ستيرات الماغنسيوم.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو شكل زاڤوكساوما&trade; هي محتويات العبوة ؟<br />&trade; زاڤوكسا هي أقراص مستدیرة الشكل، لونها ابيض إلى مائل للأبيض ، محفور عليها &quot;JP&quot;<br />من جانب و على الجانب الآخر. &quot;BL&quot;<br />۱۰ يتوفر زاڤوكسا&trade; ملجم أقراص في عبوات بداخلها ۳ أشرطة ويحتوي كل شريط<br />على ۱۰ أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسويق و المصنع:<br />شركة مصنع جمجوم للأدوية،<br />جدة، منطقة مكة، المملكة العربیة السعودية.<br />+۹٦٦-۱۲- ھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبية:<br />&bull; المملكة العربیة السعودية:<br />- المركز الوطني للتيقظ و السلامة الدوائية<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />۲۳٤۰-۲۳٥٦- تحویلة: ۲۳۱۷<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : بريد إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2020/10
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zavoxa 10 mg Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 10 mg Ezetimibe.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off white, round shaped tablets debossed with 'JP' one side and 'BL' on the other
side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary Hypercholesterolaemia<br />Ezetimibe co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as<br />adjunctive therapy to diet for use in patients with primary (heterozygous familial and nonfamilial)<br />hypercholesterolaemia who are not appropriately controlled with a statin alone.<br />Ezetimibe monotherapy is indicated as adjunctive therapy to diet for use in patients with<br />primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is<br />considered inappropriate or is not tolerated.</p><p><br />Prevention of Cardiovascular Events<br />Ezetimibe is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients<br />with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when<br />added to ongoing statin therapy or initiated concomitantly with a statin.</p><p><br />Homozygous Familial Hypercholesterolaemia (HoFH)<br />Ezetimibe co-administered with a statin, is indicated as adjunctive therapy to diet for use in<br />patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis).</p><p>Homozygous Sitosterolaemia (Phytosterolaemia)<br />Ezetimibe is indicated as adjunctive therapy to diet for use in patients with homozygous<br />familial sitosterolaemia.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The patient should be on an appropriate lipid-lowering diet and should continue on this diet<br />during treatment with Ezetimibe.</p><p><br />Route of administration is oral. The recommended dose is one Ezetimibe 10 mg tablet daily.<br />Ezetimibe can be administered at any time of the day, with or without food.</p><p><br />When Ezetimibe is added to a statin, either the indicated usual initial dose of that particular<br />statin or the already established higher statin dose should be continued. In this setting, the<br />dosage instructions for that particular statin should be consulted.</p><p><br />Use in Patients with Coronary Heart Disease and ACS Event History<br />For incremental cardiovascular event reduction in patients with coronary heart disease and<br />ACS event history, Ezetimibe 10 mg may be administered with a statin with proven<br />cardiovascular benefit.</p><p><br />Co-administration with bile acid sequestrants<br />Dosing of Ezetimibe should occur either &ge; 2 hours before or &ge; 4 hours after administration of<br />a bile acid sequestrant.</p><p><br />Elderly<br />No dosage adjustment is required for elderly patients (see section 5.2).</p><p><br />Paediatric population<br />Initiation of treatment must be performed under review of a specialist.<br />Children and adolescents &ge; 6 : The safety and efficacy of ezetimibe in children aged 6 to 17<br />years has not been established. Current available data are described in sections 4.4, 4.8, 5.1 and<br />5.2 but no recommendation on a posology can be made.</p><p>When Ezetimibe is administered with a statin, the dosage instructions for the statin in children<br />should be consulted.<br />Children &lt;6 years: The safety and efficacy of Ezetimibe in children aged &lt; 6 years has not been<br />established. No data are available.</p><p><br />Hepatic impairment<br />No dosage adjustment is required in patients with mild hepatic impairment (Child-Pugh score<br />5 to 6). Treatment with Ezetimibe is not recommended in patients with moderate (Child-Pugh<br />score 7 to 9) or severe (Child-Pugh score &gt; 9) liver dysfunction (see sections 4.4 and 5.2).</p><p><br />Renal impairment<br />No dosage adjustment is required for renally impaired patients (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
When Ezetimibe is co-administered with a statin, please refer to the SPC for that particular
medicinal product.
Therapy with Ezetimibe co-administered with a statin is contraindicated during pregnancy and
lactation.
Ezetimibe co-administered with a statin is contraindicated in patients with active liver disease
or unexplained persistent elevations in serum transaminases.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When Ezetimibe is co-administered with a statin, please refer to the SPC for that particular<br />medicinal product.<br />Liver Enzymes<br />In controlled co-administration trials in patients receiving Ezetimibe with a statin, consecutive<br />transaminase elevations (&ge; 3 X the upper limit of normal [ULN]) have been observed. When<br />Ezetimibe is co-administered with a statin, liver function tests should be performed at initiation<br />of therapy and according to the recommendations of the statin (see section 4.8).</p><p>In the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVEIT),<br />18,144 patients with coronary heart disease and ACS event history were randomised to<br />receive ezetimibe/simvastatin 10/40 mg daily (n = 9067) or simvastatin 40 mg daily (n = 9077).<br />During a median follow-up of 6.0 years, the incidence of consecutive elevations of<br />transaminases (&ge;3 X ULN) was 2.5% for ezetimibe/simvastatin and 2.3% for simvastatin (see<br />section 4.8).<br />In a controlled clinical study in which over 9000 patients with chronic kidney disease were<br />randomised to receive Ezetimibe 10 mg combined with simvastatin 20 mg daily (n = 4650) or<br />placebo (n = 4620) (median follow-up period of 4.9 years), the incidence of consecutive<br />elevations of transaminases (&gt; 3 X ULN) was 0.7% for Ezetimibe combined with simvastatin<br />and 0.6% for placebo (see section 4.8).<br />Skeletal Muscle<br />In post-marketing experience with Ezetimibe, cases of myopathy and rhabdomyolysis have<br />been reported. Most patients who developed rhabdomyolysis were taking a statin<br />concomitantly with Ezetimibe. However, rhabdomyolysis has been reported very rarely with<br />Ezetimibe monotherapy and very rarely with the addition of Ezetimibe to other agents known<br />to be associated with increased risk of rhabdomyolysis. If myopathy is suspected based on<br />muscle symptoms or is confirmed by a creatine phosphokinase (CPK) level &gt; 10 times the<br />ULN, Ezetimibe, any statin, and any of these other agents that the patient is taking<br />concomitantly should be immediately discontinued. All patients starting therapy with<br />Ezetimibe should be advised of the risk of myopathy and told to report promptly any<br />unexplained muscle pain, tenderness or weakness (see section 4.8).<br />In IMPROVE-IT, 18,144 patients with coronary heart disease and ACS event history were<br />randomised to receive ezetimibe/simvastatin 10/40 mg daily (n = 9067) or simvastatin 40 mg<br />daily (n = 9077). During a median follow-up of 6.0 years, the incidence of myopathy was 0.2%<br />for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was defined as<br />unexplained muscle weakness or pain with a serum CK &ge; 10 times ULN or two consecutive<br />observations of CK &ge; 5 and &lt; 10 times ULN. The incidence of rhabdomyolysis was 0.1% for<br />ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was defined as unexplained muscle weakness or pain with a serum CK &ge; 10 times ULN with evidence of renal<br />injury, &ge; 5 times ULN and &lt; 10 times ULN on two consecutive occasions with evidence of<br />renal injury or CK &ge; 10,000 IU/L without evidence of renal injury (see section 4.8).<br />In a clinical trial in which over 9000 patients with chronic kidney disease were randomised to<br />receive Ezetimibe 10 mg combined with simvastatin 20 mg daily (n = 4650) or placebo (n =<br />4620) (median follow-up 4.9 years), the incidence of myopathy/rhabdomyolysis was 0.2% for<br />Ezetimibe combined with simvastatin and 0.1% for placebo (see section 4.8).<br />Hepatic impairment<br />Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate<br />or severe hepatic impairment, Ezetimibe is not recommended (see section 5.2).<br />Paediatric population<br />Efficacy and safety of Ezetimibe in patients 6 to10 years of age with heterozygous familial or<br />non-familial hypercholesterolaemia have been evaluated in a 12-week placebo-controlled<br />clinical trial. Effects of ezetimibe for treatment periods &gt; 12 weeks have not been studied in<br />this age group (see sections 4.2, 4.8, 5.1 and 5.2).<br />Ezetimibe has not been studied in patients younger than 6 years of age (see sections 4.2 and<br />4.8).<br />Efficacy and safety of Ezetimibe co-administered with simvastatin in patients 10 to 17 years<br />of age with heterozygous familial hypercholesterolaemia have been evaluated in a controlled<br />clinical trial in adolescent boys (Tanner Stage II or above) and in girls who were at least one<br />year post-menarche.<br />In this limited controlled study, there was generally no detectable effect on growth or sexual<br />maturation in the adolescent boys or girls, or any effect on menstrual cycle length in girls.<br />However, the effects of ezetimibe for a treatment period &gt; 33 weeks on growth and sexual<br />maturation have not been studied (see sections 4.2 and 4.8).<br />The safety and efficacy of Ezetimibe co-administered with doses of simvastatin above 40mg<br />daily have not been studied in paediatric patients 10 to 17 years of age.</p><p>The safety and efficacy of Ezetimibe co-administered with simvastatin have not been studied<br />in paediatric patients &lt; 10 years of age (see sections 4.2 and 4.8).<br />The long-term efficacy of therapy with Ezetimibe in patients below 17 years of age to reduce<br />morbidity and mortality in adulthood has not been studied.<br />Fibrates<br />The safety and efficacy of Ezetimibe administered with fibrates have not been established.<br />If cholelithiasis is suspected in a patient receiving Ezetimibe and fenofibrate, gallbladder<br />investigations are indicated and this therapy should be discontinued (see sections 4.5 and 4.8).<br />Ciclosporin<br />Caution should be exercised when initiating Ezetimibe in the setting of ciclosporin. Ciclosporin<br />concentrations should be monitored in patients receiving Ezetimibe and ciclosporin (see section<br />4.5).<br />Anticoagulants<br />If Ezetimibe is added to warfarin, another coumarin anticoagulant, or fluindione, the<br />International Normalised Ratio (INR) should be appropriately monitored (see section 4.5).<br />Excipient<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or<br />glucose-galactose malabsorption should not take this medicine.<br />Ezetimibe contains less than 1 mmol (23 mg) sodium per tablet, that is to say essentially<br />sodium-free.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical studies, it has been shown that ezetimibe does not induce cytochrome P450 drug<br />metabolising enzymes. No clinically significant pharmacokinetic interactions have been<br />observed between ezetimibe and drugs known to be metabolised by cytochromes P450 1A2,<br />2D6, 2C8, 2C9, and 3A4, or N-acetyltransferase.</p><p>In clinical interaction studies, ezetimibe had no effect on the pharmacokinetics of dapsone,<br />dextromethorphan, digoxin, oral contraceptives (ethinyl estradiol and levonorgestrel),<br />glipizide, tolbutamide, or midazolam during co-administration. Cimetidine, co-administered<br />with ezetimibe, had no effect on the bioavailability of ezetimibe.<br />Antacids<br />Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no<br />effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered<br />clinically significant.<br />Cholestyramine<br />Concomitant cholestyramine administration decreased the mean area under the curve (AUC)<br />of total ezetimibe (ezetimibe + ezetimibe-glucuronide) approximately 55 %. The incremental<br />low-density lipoprotein cholesterol (LDL-C) reduction due to adding Ezetimibe to<br />cholestyramine may be lessened by this interaction (see section 4.2).<br />Fibrates<br />In patients receiving fenofibrate and Ezetimibe, physicians should be aware of the possible risk<br />of cholelithiasis and gallbladder disease (see sections 4.4 and 4.8).<br />If cholelithiasis is suspected in a patient receiving Ezetimibe and fenofibrate, gallbladder<br />investigations are indicated and this therapy should be discontinued (see section 4.8).<br />Concomitant fenofibrate or gemfibrozil administration modestly increased total ezetimibe<br />concentrations (approximately 1.5- and 1.7-fold respectively).<br />Co-administration of Ezetimibe with other fibrates has not been studied.<br />Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. In animal<br />studies, ezetimibe sometimes increased cholesterol in the gallbladder bile but not in all species<br />(see section 5.3). A lithogenic risk associated with the therapeutic use of Ezetimibe cannot be<br />ruled out.</p><p>Statins<br />No clinically significant pharmacokinetic interactions were seen when ezetimibe was coadministered<br />with atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin.<br />Ciclosporin<br />In a study of eight post-renal transplant patients with creatinine clearance of &gt; 50 mL/min on<br />a stable dose of ciclosporin, a single 10-mg dose of Ezetimibe resulted in a 3.4-fold (range 2.3-<br />to 7.9-fold) increase in the mean AUC for total ezetimibe compared to a healthy control<br />population, receiving ezetimibe alone, from another study (n = 17). In a different study, a renal<br />transplant patient with severe renal impairment who was receiving ciclosporin and multiple<br />other medications demonstrated a 12-fold greater exposure to total ezetimibe compared to<br />concurrent controls receiving ezetimibe alone. In a two-period crossover study in twelve<br />healthy subjects, daily administration of 20 mg ezetimibe for 8 days with a single 100-mg dose<br />of ciclosporin on Day 7 resulted in a mean 15% increase in ciclosporin AUC (range 10%<br />decrease to 51% increase) compared to a single 100-mg dose of ciclosporin alone. A controlled<br />study on the effect of co-administered ezetimibe on ciclosporin exposure in renal transplant<br />patients has not been conducted. Caution should be exercised when initiating Ezetimibe in the<br />setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving<br />Ezetimibe and ciclosporin (see section 4.4).<br />Anticoagulants<br />Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on<br />bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males.<br />However, there have been post-marketing reports of increased International Normalised Ratio<br />(INR) in patients who had Ezetimibe added to warfarin or fluindione. If Ezetimibe is added to<br />warfarin, another coumarin anticoagulant, or fluindione, INR should be appropriately<br />monitored (see section 4.4).<br />Paediatric population<br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ezetimibe co-administered with a statin is contraindicated during pregnancy and lactation (see<br />section 4.3), please refer to the SPC for that particular statin.<br />Pregnancy<br />Ezetimibe should be given to pregnant women only if clearly necessary. No clinical data are<br />available on the use of Ezetimibe during pregnancy. Animal studies on the use of ezetimibe in<br />monotherapy have shown no evidence of direct or indirect harmful effects on pregnancy,<br />embryofoetal development, birth or postnatal development (see section 5.3).<br />Lactation<br />Ezetimibe should not be used during lactation. Studies on rats have shown that ezetimibe is<br />secreted into breast milk. It is not known if ezetimibe is secreted into human breast milk.<br />Fertility<br />No clinical trial data are available on the effects of ezetimibe on human fertility. Ezetimibe had<br />no effect on the fertility of male or female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.<br />However, when driving vehicles or operating machines, it should be taken into account that<br />dizziness has been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tabulated list of adverse reactions (clinical studies and post-marketing experience)<br />In clinical studies of up to 112 weeks duration, Ezetimibe 10 mg daily was administered alone<br />in 2396 patients, with a statin in 11308 patients or with fenofibrate in 185 patients. Adverse<br />reactions were usually mild and transient. The overall incidence of side effects was similar<br />between Ezetimibe and placebo. Similarly, the discontinuation rate due to adverse experiences<br />was comparable between Ezetimibe and placebo.</p><p>Ezetimibe administered alone or co-administered with a statin:<br />The following adverse reactions were observed in patients treated with Ezetimibe (n = 2396)<br />and at a greater incidence than placebo (n = 1159) or in patients treated with Ezetimibe<br />coadministered with a statin (n = 11308) and at a greater incidence than statin administered<br />alone (n = 9361). Post-marketing Adverse reactions were derived from reports containing<br />Ezetimibe either administered alone or with a statin. Adverse reactions observed in clinical<br />studies of Ezetimibe (as a monotherapy or co-administered with a statin) or Ezetimibe reported<br />from post-marketing use either administered alone or with a statin are listed in Table 1. These<br />reactions are presented by system organ class and by frequency.<br />Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon<br />(&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known<br />(cannot be estimated from the available data).</p><table cellspacing="1" cellpadding="1" border="1" style="width:500px"><tbody><tr><td style="width:246px"><strong>System organ class<br />Frequency</strong></td><td style="width:252px"><strong>Adverse reaction</strong></td></tr><tr><td colspan="2" style="width:246px"><strong>Blood and lymphatic system disorders</strong></td></tr><tr><td style="width:246px">Not known</td><td style="width:252px">&nbsp;Thrombocytopaein</td></tr><tr><td colspan="2" style="width:246px"><strong>Immune system disorders</strong></td></tr><tr><td style="width:246px">Not known</td><td style="width:252px">hypersensitivity; including rash; urticaria; anaphylaxis<br />and angio-oedema</td></tr><tr><td colspan="2" style="width:246px"><strong>Metabolism and nutrition disorders</strong></td></tr><tr><td style="width:246px">Uncommon</td><td style="width:252px">decreased appetite</td></tr><tr><td colspan="2" style="width:246px"><strong>Psychiatric disorders</strong></td></tr><tr><td style="width:246px">Not known</td><td style="width:252px">depression</td></tr><tr><td colspan="2" style="width:246px"><strong>Nervous system disorders</strong></td></tr><tr><td style="width:246px">Common</td><td style="width:252px">headache</td></tr><tr><td style="width:246px">Uncommon</td><td style="width:252px">paraesthesia</td></tr><tr><td style="width:246px">Not known</td><td style="width:252px">dizziness</td></tr><tr><td colspan="2" style="width:246px"><strong>Vascular disorders</strong></td></tr><tr><td style="width:246px">Uncommon</td><td style="width:252px">hot flush; hypertension</td></tr><tr><td colspan="2" style="width:246px"><strong>Respiratory, thoracic and mediastinal disorders<br />Uncommon</strong><table cellspacing="1" cellpadding="1" border="1" style="width:500px"><tbody><tr><td style="width:238px">Uncommon</td><td style="width:260px">cough</td></tr><tr><td style="width:238px">Not known</td><td style="width:260px">dyspnoea</td></tr><tr><td colspan="2" style="width:238px"><strong>Gastrointestinal disorders</strong></td></tr><tr><td style="width:238px">Common</td><td style="width:260px">abdominal pain; diarrhoea; flatulence</td></tr><tr><td style="width:238px">Uncommon</td><td style="width:260px">dyspepsia; gastrooesophageal reflux disease; nausea; dry<br />mouth; gastritis</td></tr><tr><td style="width:238px">Not known</td><td style="width:260px">pancreatitis; constipation</td></tr><tr><td colspan="2" style="width:238px"><strong>Hepatobiliary disorders</strong></td></tr><tr><td style="width:238px">Not known</td><td style="width:260px">hepatitis; cholelithiasis; cholecystitis</td></tr><tr><td colspan="2" style="width:238px"><strong>Skin and subcutaneous tissue disorders</strong></td></tr><tr><td style="width:238px">Uncommon</td><td style="width:260px">pruritus; rash; urticaria</td></tr><tr><td style="width:238px">Not known</td><td style="width:260px">erythema multiforme</td></tr><tr><td colspan="2" style="width:238px"><strong>Musculoskeletal and connective tissue disorders</strong></td></tr><tr><td style="width:238px">Common</td><td style="width:260px">myalgia</td></tr><tr><td style="width:238px">Uncommon</td><td style="width:260px">arthralgia; muscle spasms; neck pain; back pain;<br />muscular weakness; pain in extremity</td></tr><tr><td style="width:238px">Not known</td><td style="width:260px">myopathy/rhabdomyolysis (see section 4.4)</td></tr><tr><td colspan="2" style="width:238px"><strong>General disorders and administration site conditions</strong></td></tr><tr><td style="width:238px">Common</td><td style="width:260px">fatigue</td></tr><tr><td style="width:260px">chest pain; pain; asthenia; oedema peripheral</td></tr><tr><td colspan="2" style="width:238px"><strong>Investigations</strong></td></tr><tr><td style="width:238px">Common</td><td style="width:260px">ALT and/or AST increased</td></tr><tr><td style="width:238px">Uncommon</td><td style="width:260px">blood CPK increased; gamma-glutamyltransferase<br />increased; liver function test abnormal</td></tr></tbody></table></td></tr></tbody></table><p>Ezetimibe co-administered with fenofibrate<br />Gastrointestinal disorders: abdominal pain (common)<br />In a multicentre, double-blind, placebo-controlled, clinical study in patients with mixed<br />hyperlipidaemia, 625 patients were treated for up to 12 weeks and 576 patients for up to 1 year.<br />In this study, 172 patients treated with Ezetimibe and fenofibrate completed 12 weeks of<br />therapy, and 230 patients treated with Ezetimibe and fenofibrate (including 109 who received<br />Ezetimibe alone for the first 12 weeks) completed 1 year of therapy. This study was not<br />designed to compare treatment groups for infrequent events. Incidence rates (95% CI) for<br />clinically important elevations (&gt; 3 X ULN, consecutive) in serum transaminases were 4.5%<br />(1.9, 8.8) and 2.7% (1.2, 5.4) for fenofibrate monotherapy and Ezetimibe co-administered with<br />fenofibrate, respectively, adjusted for treatment exposure. Corresponding incidence rates for<br />cholecystectomy were 0.6% (0.0, 3.1) and 1.7% (0.6, 4.0) for fenofibrate monotherapy and<br />Ezetimibe co-administered with fenofibrate, respectively (see sections 4.4 and 4.5).</p><p>Paediatric (6 to 17 years of age) Patients<br />In a study involving paediatric (6 to 10 years of age) patients with heterozygous familial or<br />non-familial hypercholesterolaemia (n = 138), elevations of ALT and/or AST (&ge; 3 X ULN,<br />consecutive) were observed in 1.1% (1 patient) of the ezetimibe patients compared to 0% in<br />the placebo group. There were no elevations of CPK (&ge; 10 X ULN). No cases of myopathy<br />were reported.<br />In a separate study involving adolescent (10 to 17 years of age) patients with heterozygous<br />familial hypercholesterolaemia (n = 248), elevations of ALT and/or AST (&ge; 3 X ULN,<br />consecutive) were observed in 3% (4 patients) of the ezetimibe/simvastatin patients compared<br />to 2% (2 patients) in the simvastatin monotherapy group; these figures were respectively 2%<br />(2 patients) and 0% for elevation of CPK (&ge; 10 X ULN). No cases of myopathy were reported.<br />These trials were not suited for comparison of rare adverse drug reactions.<br />Patients with Coronary Heart Disease and ACS Event History<br />In the IMPROVE-IT study (see section 5.1), involving 18144 patients treated with either<br />ezetimibe/simvastatin 10/40 mg (n = 9067; of whom 6% were uptitrated to<br />ezetimibe/simvastatin 10/80 mg) or simvastatin 40 mg (n = 9077; of whom 27% were uptitrated<br />to simvastatin 80 mg), the safety profiles were similar during a median follow-up period of 6.0<br />years. Discontinuation rates due to adverse experiences were 10.6% for patients treated with<br />ezetimibe/simvastatin and 10.1% for patients treated with simvastatin. The incidence of<br />myopathy was 0.2% for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was<br />defined as unexplained muscle weakness or pain with a serum CK &ge; 10 times ULN or two<br />consecutive observations of CK &ge; 5 and &lt; 10 times ULN. The incidence of rhabdomyolysis<br />was 0.1% for ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was<br />defined as unexplained muscle weakness or pain with a serum CK &ge; 10 times ULN with<br />evidence of renal injury, &ge; 5 times ULN and &lt; 10 times ULN on two consecutive occasions<br />with evidence of renal injury or CK &ge; 10,000 IU/L without evidence of renal injury. The<br />incidence of consecutive elevations of transaminases (&ge; 3 X ULN) was 2.5% for<br />ezetimibe/simvastatin and 2.3% for simvastatin (see section 4.4). Gallbladder-related adverse<br />effects were reported in 3.1% vs 3.5% of patients allocated to ezetimibe/simvastatin and<br />simvastatin, respectively. The incidence of cholecystectomy hospitalisations was 1.5% in both<br />treatment groups. Cancer (defined as any new malignancy) was diagnosed during the trial in<br />9.4% vs 9.5%, respectively.<br />Patients with Chronic Kidney Disease<br />In the Study of Heart and Renal Protection (SHARP) (see section 5.1), involving over 9000<br />patients treated with a fixed dose combination of Ezetimibe 10 mg with simvastatin 20 mg<br />daily (n = 4650) or placebo (n = 4620), the safety profiles were comparable during a median<br />follow-up period of 4.9 years. In this trial, only serious adverse events and discontinuations</p><p>due to any adverse events were recorded. Discontinuation rates due to adverse events were<br />comparable (10.4% in patients treated with Ezetimibe combined with simvastatin, 9.8% in<br />patients treated with placebo). The incidence of myopathy/rhabdomyolysis was 0.2% in<br />patients treated with Ezetimibe combined with simvastatin and 0.1% in patients treated with<br />placebo. Consecutive elevations of transaminases (&gt; 3X ULN) occurred in 0.7% of patients<br />treated with Ezetimibe combined with simvastatin compared with 0.6% of patients treated with<br />placebo (see section 4.4). In this trial, there were no statistically significant increases in the<br />incidence of pre-specified adverse events, including cancer (9.4% for Ezetimibe combined with<br />simvastatin, 9.5% for placebo), hepatitis, cholecystectomy or complications of gallstones or<br />pancreatitis.<br />Laboratory values:<br />In controlled clinical monotherapy trials, the incidence of clinically important elevations in<br />serum transaminases (ALT and/or AST &ge; 3 X ULN, consecutive) was similar between<br />Ezetimibe (0.5%) and placebo (0.3%). In co-administration trials, the incidence was 1.3% for<br />patients treated with Ezetimibe co-administered with a statin and 0.4% for patients treated with<br />a statin alone. These elevations were generally asymptomatic, not associated with cholestasis,<br />and returned to baseline after discontinuation of therapy or with continued treatment (see<br />section 4.4).<br />In clinical trials, CPK &gt; 10 X ULN was reported for 4 of 1674 (0.2%) patients administered<br />Ezetimibe alone vs 1 of 786 (0.1%) patients administered placebo, and for 1 of 917 (0.1%)<br />patients co-administered Ezetimibe and a statin vs 4 of 929 (0.4%) patients administered a<br />statin alone. There was no excess of myopathy or rhabdomyolysis associated with Ezetimibe<br />compared with the relevant control arm (placebo or statin alone) (see section 4.4).<br />To reports any side effect(s):<br />&bull; Saudi Arabia<br />-The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317--2356-2340.<br />Toll free phone: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14<br />days, or 40 mg/day to 18 patients with primary hypercholesterolaemia for up to 56 days, was generally well tolerated. In animals, no toxicity was observed after single oral doses of 5000<br />mg/kg of ezetimibe in rats and mice and 3000 mg/kg in dogs.<br />A few cases of overdosage with Ezetimibe have been reported; most have not been associated<br />with adverse experiences. Reported adverse experiences have not been serious. In the event of<br />an overdose, symptomatic and supportive measures should be employed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other lipid modifying agents, ATC code: C10A X09<br />Mechanism of action<br />Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal<br />absorption of cholesterol and related plant sterols. Ezetimibe is orally active and has a<br />mechanism of action that differs from other classes of cholesterol-reducing compounds (e.g.<br />statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular<br />target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is<br />responsible for the intestinal uptake of cholesterol and phytosterols.<br />Ezetimibe localises at the brush border of the small intestine and inhibits the absorption of<br />cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver; statins<br />reduce cholesterol synthesis in the liver and together these distinct mechanisms provide<br />complementary cholesterol reduction. In a 2-week clinical study in 18 hypercholesterolaemic<br />patients, Ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo.<br />Pharmacodynamic effects<br />A series of preclinical studies was performed to determine the selectivity of ezetimibe for<br />inhibiting cholesterol absorption. Ezetimibe inhibited the absorption of [14C]-cholesterol with<br />no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl<br />estradiol, or fat-soluble vitamins A and D.<br />Epidemiologic studies have established that cardiovascular morbidity and mortality vary<br />directly with the level of total-C and LDL-C and inversely with the level of HDL-C.</p><p>Administration of Ezetimibe with a statin is effective in reducing the risk of cardiovascular<br />events in patients with coronary heart disease and ACS event history.<br />Clinical efficacy and safety<br />In controlled clinical studies, Ezetimibe either as monotherapy or co-administered with a statin<br />significantly reduced total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C),<br />apolipoprotein B (Apo B), and triglycerides (TG) and increased high-density lipoprotein<br />cholesterol (HDL-C) in patients with hypercholesterolaemia.<br />Primary Hypercholesterolaemia<br />In a double-blind, placebo-controlled, 8-week study, 769 patients with hypercholesterolaemia<br />already receiving statin monotherapy and not at National Cholesterol Education Program<br />(NCEP) LDL-C goal (2.6 to 4.1 mmol/L [100 to 160 mg/dL], depending on baseline<br />characteristics) were randomised to receive either Ezetimibe 10 mg or placebo in addition to<br />their on-going statin therapy.<br />Among statin-treated patients not at LDL-C goal at baseline (~82%), significantly more<br />patients randomised to Ezetimibe achieved their LDL-C goal at study endpoint compared to<br />patients randomised to placebo, 72% and 19%, respectively. The corresponding LDL-C<br />reductions were significantly different (25% and 4% for Ezetimibe versus placebo,<br />respectively). In addition, Ezetimibe, added to on-going statin therapy, significantly decreased<br />total-C, Apo B, TG and increased HDL-C, compared with placebo. Ezetimibe or placebo added<br />to statin therapy reduced median C-reactive protein by 10% or 0% from baseline, respectively.<br />In two, double-blind, randomised placebo-controlled, 12-week studies in 1719 patients with<br />primary hypercholesterolaemia, Ezetimibe 10 mg significantly lowered total-C (13%), LDL-C<br />(19%), Apo B (14%), and TG (8%) and increased HDL-C (3%) compared to placebo. In<br />addition, Ezetimibe had no effect on the plasma concentrations of fat-soluble vitamins A, D,<br />and E, no effect on prothrombin time, and, like other lipid lowering agents, did not impair<br />adrenocortical steroid hormone production.<br />In a multicenter, double-blind, controlled clinical study (ENHANCE), 720 patients with<br />heterozygous familial hypercholesterolaemia were randomised to receive ezetimibe 10 mg in</p><p>combination with simvastatin 80 mg (n = 357) or simvastatin 80 mg (n = 363) for 2 years. The<br />primary objective of the study was to investigate the effect of the ezetimibe/simvastatin<br />combination therapy on carotid artery intima-media thickness (IMT) compared to simvastatin<br />monotherapy. The impact of this surrogate marker on cardiovascular morbidity and mortality<br />is still not demonstrated.<br />The primary endpoint, the change in the mean IMT of all six carotid segments, did not differ<br />significantly (p = 0.29) between the two treatment groups as measured by B-mode ultrasound.<br />With ezetimibe 10 mg in combination with simvastatin 80 mg or simvastatin 80 mg alone,<br />intima-medial thickening increased by 0.0111 mm and 0.0058 mm, respectively, over the<br />study&#39;s 2 year duration (baseline mean carotid IMT 0.68 mm and 0.69 mm respectively.<br />Ezetimibe 10 mg in combination with simvastatin 80 mg lowered LDL-C, total-C, Apo B, and<br />TG significantly more than simvastatin 80 mg. The percent increase in HDL-C was similar for<br />the two treatment groups. The adverse reactions reported for ezetimibe 10 mg in combination<br />with simvastatin 80 mg were consistent with its known safety profile.<br />Paediatric population<br />In a multicentre, double-blind, controlled study, 138 patients (59 boys and 79 girls), 6 to 10<br />years of age (mean age 8.3 years) with heterozygous familial or non-familial<br />hypercholesterolaemia (HeFH) with baseline LDL-C levels between 3.74 and 9.92 mmol/L<br />were randomised to either Ezetimibe 10 mg or placebo for 12 weeks.<br />At week 12, Ezetimibe significantly reduced total-C (-21% vs. 0%), LDL-C (-28% vs. -1%),<br />Apo-B (-22% vs. -1%), and non-HDL-C (-26% vs. 0%) compared to placebo. Results for the<br />two treatment groups were similar for TG and HDL-C (-6% vs. +8%, and +2% vs. +1%,<br />respectively).<br />In a multicentre, double-blind, controlled study, 142 boys (Tanner Stage II and above) and 106<br />postmenarchal girls, 10 to 17 years of age (mean age 14.2 years) with heterozygous familial<br />hypercholesterolaemia (HeFH) with baseline LDL-C levels between 4.1 and 10.4 mmol/L were<br />randomised to either Ezetimibe 10 mg co-administered with simvastatin (10, 20 or 40 mg) or<br />simvastatin (10, 20 or 40 mg) alone for 6 weeks, co-administered Ezetimibe and 40 mg</p><p>simvastatin or 40 mg simvastatin alone for the next 27 weeks, and open-label co-administered<br />Ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter.<br />At Week 6, Ezetimibe co-administered with simvastatin (all doses) significantly reduced total-<br />C (38% vs 26%), LDL-C (49% vs 34%), Apo B (39% vs 27%), and non-HDL-C (47% vs 33%)<br />compared to simvastatin (all doses) alone. Results for the two treatment groups were similar<br />for TG and HDL-C (-17% vs -12% and +7% vs +6%, respectively). At Week 33, results were<br />consistent with those at Week 6 and significantly more patients receiving Ezetimibe and 40 mg<br />simvastatin (62%) attained the NCEP AAP ideal goal (&lt; 2.8 mmol/L [110 mg/dL]) for LDL-C<br />compared to those receiving 40 mg simvastatin (25%). At Week 53, the end of the open label<br />extension, the effects on lipid parameters were maintained.<br />The safety and efficacy of Ezetimibe co-administered with doses of simvastatin above 40 mg<br />daily have not been studied in paediatric patients 10 to 17 years of age. The safety and efficacy<br />of Ezetimibe co-administered with simvastatin have not been studied in paediatric patients &lt;<br />10 years of age.<br />The long-term efficacy of therapy with Ezetimibe in patients below 17 years of age to reduce<br />morbidity and mortality in adulthood has not been studied.<br />Prevention of Cardiovascular Events<br />The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)<br />was a multicenter, randomised, double-blind, active-control study of 18,144 patients enrolled<br />within 10 days of hospitalisation for acute coronary syndrome (ACS; either acute myocardial<br />infarction [MI] or unstable angina [UA]). Patients had an LDL-C &le; 125 mg/dL (&le; 3.2 mmol/L)<br />at the time of presentation with ACS if they had not been taking lipid-lowering therapy, or &le;<br />100 mg/dL (&le; 2.6 mmol/L) if they had been receiving lipid-lowering therapy. All patients were<br />randomised in a 1:1 ratio to receive either ezetimibe/simvastatin 10/40 mg (n = 9067) or<br />simvastatin 40 mg (n = 9077) and followed for a median of 6.0 years.<br />Patients had a mean age of 63.6 years; 76% were male, 84% were Caucasian, and 27% were<br />diabetic. The average LDL-C value at the time of study qualifying event was 80 mg/dL (2.1<br />mmol/L) for those on lipid-lowering therapy (n = 6390) and 101 mg/dL (2.6 mmol/L) for those<br />not on previous lipid-lowering therapy (n = 11594). Prior to the hospitalisation for the qualifying ACS event, 34% of the patients were on statin therapy. At one year, the average<br />LDL-C for patients continuing on therapy was 53.2 mg/dL (1.4 mmol/L) for the<br />ezetimibe/simvastatin group and 69.9 mg/dL (1.8 mmol/L) for the simvastatin monotherapy<br />group. Lipid values were generally obtained for patients who remained on study therapy.<br />The primary endpoint was a composite consisting of cardiovascular death, major coronary<br />events (MCE; defined as non-fatal myocardial infarction, documented unstable angina that<br />required hospitalisation, or any coronary revascularisation procedure occurring at least 30 days<br />after randomised treatment assignment) and non-fatal stroke. The study demonstrated that<br />treatment with ezetimibe when added to simvastatin provided incremental benefit in reducing<br />the primary composite endpoint of cardiovascular death, MCE, and non-fatal stroke compared<br />with simvastatin alone (relative risk reduction of 6.4%, p = 0.016). The primary endpoint<br />occurred in 2572 of 9067 patients (7-year Kaplan-Meier [KM] rate 32.72%) in the<br />ezetimibe/simvastatin group and 2742 of 9077 patients (7-year KM rate 34.67%) in the<br />simvastatin alone group (see Figure 1 and Table 2). This incremental benefit is expected to be<br />similar with coadministration of other statins shown to be effective in reducing the risk of<br />cardiovascular events. Total mortality was unchanged in this high risk group (see Table 2).<br />There was an overall benefit for all strokes; however there was a small non-significant increase<br />in haemorrhagic stroke in the ezetimibe-simvastatin group compared with simvastatin alone<br />(see Table 2). The risk of haemorrhagic stroke for ezetimibe coadministered with higher<br />potency statins in long-term outcome studies has not been evaluated.<br />The treatment effect of ezetimibe/simvastatin was generally consistent with the overall results<br />across many subgroups, including sex, age, race, medical history of diabetes mellitus, baseline<br />lipid levels, prior statin therapy, prior stroke, and hypertension.<br />Figure 1: Effect of Ezetimibe/Simvastatin on the Primary Composite Endpoint of<br />Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke</p><p><img src="data:image/png;base64,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" /></p><p>Table 2<br />Major Cardiovascular Events by Treatment Group in All Randomised Patients in IMPROVEIT</p><p>VZ</p><table cellspacing="1" cellpadding="1" border="1" style="width:500px"><tbody><tr><td style="width:77px">outcome</td><td rowspan="1" colspan="2" style="width:108px">Ezetimibe/Simvastatin<br />10/40 mga<br />(n = 9067)</td><td rowspan="1" colspan="2" style="width:114px">Simvastatin<br />40 mgb<br />(n = 9077)</td><td style="width:54px">Hazard Ratio<br />(95% CI)</td><td style="width:51px">p-value</td></tr><tr><td style="width:77px">&nbsp;</td><td style="width:108px">n</td><td style="width:105px">K-M % <sup>c</sup></td><td style="width:49px">n</td><td style="width:60px">K-M % <sup>c</sup></td><td style="width:54px">&nbsp;</td><td style="width:51px">&nbsp;</td></tr><tr><td colspan="7" style="width:93px">Primary Composite Efficacy Endpoint</td></tr><tr><td style="width:77px">(CV death, Major Coronary<br />Events and non-fatal stroke)</td><td style="width:108px">2572</td><td style="width:105px">32.72%</td><td style="width:49px">2742</td><td style="width:60px">34.67%</td><td style="width:54px">0.936 (0.887,<br />0.988)</td><td style="width:51px">0.016</td></tr><tr><td colspan="7" style="width:77px">Secondary Composite Efficacy Endpoints</td></tr><tr><td style="width:77px">CHD death, nonfatal MI, urgent<br />coronary revascularisation after<br />30 days</td><td style="width:108px">1322</td><td style="width:105px">7.52%</td><td style="width:49px">1448</td><td style="width:60px">18.88%</td><td style="width:54px">0.912 (0.847,<br />0.983)</td><td style="width:51px">0.016</td></tr><tr><td style="width:77px">MCE, non-fatal stroke, death<br />(all causes)</td><td style="width:108px">3089</td><td style="width:105px">38.65%</td><td style="width:49px">3256</td><td style="width:60px">40.25%</td><td style="width:54px">0.948 (0.903,<br />0.996)</td><td style="width:51px">0.035</td></tr><tr><td style="width:77px">CV death, non-fatal MI,<br />unstable angina requiring<br />hospitalisation, any<br />revascularisation, non-fatal<br />stroke</td><td style="width:108px">2716</td><td style="width:105px">34.49%</td><td style="width:49px">2869</td><td style="width:60px">36.20%</td><td style="width:54px">0.945 (0.897,<br />0.996)</td><td style="width:51px">0.035</td></tr><tr><td style="width:77px">Cardiovascular death</td><td style="width:108px">537</td><td style="width:105px">6.89%</td><td style="width:49px">538</td><td style="width:60px">6.84%</td><td style="width:54px">1.000 (0.887,<br />1.127)</td><td style="width:51px">0.997</td></tr><tr><td colspan="7" style="width:77px">Major Coronary Event:</td></tr><tr><td style="width:77px">Non-fatal MI</td><td style="width:108px">945</td><td style="width:105px">12.77%</td><td style="width:49px">1083</td><td style="width:60px">14.41%</td><td style="width:54px">0.871 (0.798,<br />0.950)</td><td style="width:51px">0.002</td></tr><tr><td style="width:77px">Unstable angina requiring<br />hospitalisation</td><td style="width:108px">156</td><td style="width:105px">2.06%</td><td style="width:49px">148</td><td style="width:60px">1.92%</td><td style="width:54px">1.059 (0.846,<br />1.326)</td><td style="width:51px">0.618</td></tr><tr><td style="width:77px">Coronary revascularisation<br />after 30 days</td><td style="width:108px">1690</td><td style="width:105px">21.84%</td><td style="width:49px">1793</td><td style="width:60px">23.36%</td><td style="width:54px">0.947 (0.886,<br />1.012)</td><td style="width:51px">0.107</td></tr><tr><td style="width:77px">Non-fatal stroke</td><td style="width:108px">245</td><td style="width:105px">3.49%</td><td style="width:49px">305</td><td style="width:60px">4.24%</td><td style="width:54px">0.802 (0.678,<br />0.949)</td><td style="width:51px">0.010</td></tr><tr><td style="width:77px">All MI (fatal and non-fatal)</td><td style="width:108px">977</td><td style="width:105px">13.13%</td><td style="width:49px">1118</td><td style="width:60px">14.82%</td><td style="width:54px">0.872 (0.800,<br />0.950)</td><td style="width:51px">0.002</td></tr><tr><td style="width:77px">All stroke (fatal and non-fatal)</td><td style="width:108px">296</td><td style="width:105px">4.16%</td><td style="width:49px">345</td><td style="width:60px">4.77%</td><td style="width:54px">0.857 (0.734,<br />1.001)</td><td style="width:51px">0.052</td></tr><tr><td style="width:77px">Non-haemorrhagic stroke d</td><td style="width:108px">242</td><td style="width:105px">3.48%</td><td style="width:49px">305</td><td style="width:60px">4.23%</td><td style="width:54px">0.793 (0.670,<br />0.939)</td><td style="width:51px">0.007</td></tr><tr><td style="width:77px">Haemorrhagic stroke</td><td style="width:108px">59</td><td style="width:105px">0.77%</td><td style="width:49px">43</td><td style="width:60px">0.59%</td><td style="width:54px">1.377 (0.930,<br />2.040)</td><td style="width:51px">0.110</td></tr><tr><td style="width:77px">Death from any cause</td><td style="width:108px">1215</td><td style="width:105px">1231</td><td style="width:49px">15.28%</td><td style="width:60px">15.28%</td><td style="width:54px">0.989 (0.914,<br />1.070)</td><td style="width:51px">0.782</td></tr></tbody></table><p><sup>a</sup> 6% were uptitrated to ezetimibe/simvastatin 10/80 mg.<br /><sup>b</sup> 27% were uptitrated to simvastatin 80 mg.<br /><sup>c </sup>Kaplan-Meier estimate at 7 years.<br /><sup>d</sup> includes ischemic stroke or stroke of undetermined type.<br />Prevention of Major Vascular Events in Chronic Kidney Disease (CKD)<br />The Study of Heart and Renal Protection (SHARP) was a multi-national, randomised, placebocontrolled,<br />double-blind study conducted in 9438 patients with chronic kidney disease, a third<br />of whom were on dialysis at baseline. A total of 4650 patients were allocated to a fixed dose<br />combination of Ezetimibe 10 mg with simvastatin 20 mg and 4620 to placebo, and followed<br />for a median of 4.9 years. Patients had a mean age of 62 and 63% were male, 72% Caucasian,<br />23% diabetic and, for those not on dialysis, the mean estimated glomerular filtration rate<br />(eGFR) was 26.5 mL/min/1.73 m2. There were no lipid entry criteria. Mean LDL-C at baseline<br />was 108 mg/dL. After one year, including patients no longer taking study medication, LDL-C<br />was reduced 26% relative to placebo by simvastatin 20 mg alone and 38% by Ezetimibe 10 mg<br />combined with simvastatin 20 mg.<br />The SHARP protocol-specified primary comparison was an intention-to-treat analysis of<br />&quot;major vascular events&quot; (MVE; defined as nonfatal MI or cardiac death, stroke, or any<br />revascularisation procedure) in only those patients initially randomised to the Ezetimibe<br />combined with simvastatin (n = 4193) or placebo (n = 4191) groups. Secondary analyses<br />included the same composite analyzed for the full cohort randomised (at study baseline or at<br />year 1) to Ezetimibe combined with simvastatin (n = 4650) or placebo (n = 4620) as well as<br />the components of this composite.</p><p>The primary endpoint analysis showed that Ezetimibe combined with simvastatin significantly<br />reduced the risk of major vascular events (749 patients with events in the placebo group vs.<br />639 in the Ezetimibe combined with simvastatin group) with a relative risk reduction of 16%<br />(p = 0.001).<br />Nevertheless, this study design did not allow for a separate contribution of the monocomponent<br />ezetimibe to efficacy to significantly reduce the risk of major vascular events in patients with<br />CKD.<br />The individual components of MVE in all randomised patients are presented in Table 3.<br />Ezetimibe combined with simvastatin significantly reduced the risk of stroke and any<br />revascularisation, with non-significant numerical differences favouring Ezetimibe combined<br />with simvastatin for nonfatal MI and cardiac death.<br />Table 3<br />Major Vascular Events by Treatment Group in all randomised patients in SHARP<sup>a </sup></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="border-color:#7a7a7a; height:85.75pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:0in"><u>Outcome</u></p></td><td style="border-color:#7a7a7a; height:85.75pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:.6pt; text-align:justify">Ezetimibe 10 mg combined with simvastatin 20 mg</p><p style="margin-left:1.5pt; text-align:justify">(n = 4650)</p></td><td style="border-color:#7a7a7a; height:85.75pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:29.8pt"><u>Placebo</u> (n = 4620)</p></td><td style="border-color:#7a7a7a; height:85.75pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:59.8pt"><u>Risk Ratio</u> <u>(95% CI)</u></p></td><td style="border-color:#7a7a7a; height:85.75pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in"><u>P-value</u></p></td></tr><tr><td style="border-color:#7a7a7a; height:23.7pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:0in">Major Vascular Events</p></td><td style="height:23.7pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:0in">701 (15.1%)</p></td><td style="height:23.7pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:0in">814 (17.6%)</p></td><td style="height:23.7pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:0in">0.85 (0.77-0.94)</p></td><td style="height:23.7pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in">0.001</p></td></tr><tr><td style="border-color:#7a7a7a; height:23.65pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:0in">Nonfatal MI</p></td><td style="height:23.65pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:0in">134 (2.9%)</p></td><td style="height:23.65pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:0in">159 (3.4%)</p></td><td style="height:23.65pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:0in">0.84 (0.66-1.05)</p></td><td style="height:23.65pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in">0.12</p></td></tr><tr><td style="border-color:#7a7a7a; height:23.65pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:0in">Cardiac Death</p></td><td style="height:23.65pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:0in">253 (5.4%)</p></td><td style="height:23.65pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:0in">272 (5.9%)</p></td><td style="height:23.65pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:0in">0.93 (0.78-1.10)</p></td><td style="height:23.65pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in">0.38</p></td></tr><tr><td style="border-color:#7a7a7a; height:23.7pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:0in">Any Stroke</p></td><td style="height:23.7pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:0in">171 (3.7%)</p></td><td style="height:23.7pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:0in">210 (4.5%)</p></td><td style="height:23.7pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:0in">0.81 (0.66-0.99)</p></td><td style="height:23.7pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in">0.038</p></td></tr><tr><td style="border-color:#7a7a7a; height:23.65pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:0in">Non-haemorrhagic Stroke</p></td><td style="height:23.65pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:0in">131 (2.8%)</p></td><td style="height:23.65pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:0in">174 (3.8%)</p></td><td style="height:23.65pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:0in">0.75 (0.60-0.94)</p></td><td style="height:23.65pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in">0.011</p></td></tr><tr><td style="border-color:#7a7a7a; height:23.7pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:0in">Haemorrhagic Stroke</p></td><td style="height:23.7pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:0in">45 (1.0%)</p></td><td style="height:23.7pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:0in">37 (0.8%)</p></td><td style="height:23.7pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:0in">1.21 (0.78-1.86)</p></td><td style="height:23.7pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in">0.40</p></td></tr><tr><td style="border-color:#7a7a7a; height:23.65pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:0in">Any Revascularisation</p></td><td style="height:23.65pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:0in">284 (6.1%)</p></td><td style="height:23.65pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:0in">352 (7.6%)</p></td><td style="height:23.65pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:0in">0.79 (0.68-0.93)</p></td><td style="height:23.65pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in">0.004</p></td></tr><tr><td style="border-color:#7a7a7a; height:44.4pt; vertical-align:top; width:165.85pt"><p style="margin-left:1.45pt; margin-right:.7pt">Major&nbsp;&nbsp;&nbsp;&nbsp; Atherosclerotic&nbsp;&nbsp;&nbsp;&nbsp; Events (MAE)b</p></td><td style="height:44.4pt; vertical-align:top; width:93.3pt"><p style="margin-left:1.5pt; margin-right:0in">526 (11.3%)</p></td><td style="height:44.4pt; vertical-align:top; width:82.95pt"><p style="margin-left:1.5pt; margin-right:0in">619 (13.4%)</p></td><td style="height:44.4pt; vertical-align:top; width:114.0pt"><p style="margin-left:1.4pt; margin-right:0in">0.83 (0.74-0.94)</p></td><td style="height:44.4pt; vertical-align:top; width:62.2pt"><p style="margin-left:1.4pt; margin-right:0in">0.002</p></td></tr></tbody></table><p style="margin-left:10.0pt; margin-right:71.9pt; text-align:justify">aIntention-to-treat analysis on all SHARP patients randomised to Ezetimibe combined with simvstatin or placebo either at baseline or year 1</p><p style="margin-left:10.0pt; margin-right:71.8pt; text-align:justify">b MAE; defined as the composite of nonfatal myocardial infarction, coronary death, non- hemorrhagic stroke, or any revascularisation</p><p style="margin-left:10.0pt; margin-right:71.9pt; text-align:justify">The absolute reduction in LDL cholesterol achieved with Ezetimibe combined with simvastatin was lower among patients with a lower baseline LDL-C (&lt;2.5 mmol/L) and patients on dialysis at baseline than the other patients, and the corresponding risk reductions in these two groups were attenuated.</p><p style="margin-left:10.0pt; margin-right:0in"><em>Homozygous Familial Hypercholesterolaemia (HoFH)</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p style="margin-right:71.85pt; text-align:justify">A double-blind, randomised, 12-week study enrolled 50 patients with a clinical and/or genotypic diagnosis of HoFH, who were receiving atorvastatin or simvastatin (40 mg) with or without concomitant LDL apheresis. Ezetimibe co-administered with atorvastatin (40 or 80 mg) or simvastatin (40 or 80 mg), significantly reduced LDL-C by 15% compared with increasing the dose of simvastatin or atorvastatin monotherapy from 40 to 80 mg.</p><p style="margin-left:10.0pt; margin-right:0in"><em>Homozygous Sitosterolaemia (Phytosterolaemia)</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p style="margin-right:71.8pt; text-align:justify">In a double-blind, placebo-controlled, 8-week trial, 37 patients with homozygous sitosterolaemia were randomised to receive Ezetimibe 10 mg (n = 30) or placebo (n = 7). Some patients were receiving other treatments (e.g. statins, resins). Ezetimibe significantly lowered the two major plant sterols, sitosterol and campesterol, by 21% and 24% from baseline, respectively. The effects of decreasing sitosterol on morbidity and mortality in this population are not known.</p><p style="margin-left:10.0pt; margin-right:0in"><em>Aortic Stenosis</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p style="margin-right:71.8pt; text-align:justify">The Simvastatin and Ezetimibe for the Treatment of Aortic Stenosis (SEAS) study was a multi- center, double-blind, placebo-controlled study with a median duration of 4.4 years conducted in 1873 patients with asymptomatic aortic stenosis (AS), documented by Doppler-measured aortic peak flow velocity within the range of 2.5 to 4.0 m/s. Only patients who were considered not to require statin treatment for purposes of reducing atherosclerotic cardiovascular disease</p><p style="margin-left:10.0pt; margin-right:71.8pt; text-align:justify">risk were enrolled. Patients were randomised 1:1 to receive placebo or co-administered ezetimibe 10 mg and simvastatin 40 mg daily.</p><p style="margin-left:10.0pt; margin-right:71.95pt; text-align:justify">The primary endpoint was the composite of major cardiovascular events (MCE) consisting of cardiovascular death, aortic valve replacement (AVR) surgery, congestive heart failure (CHF) as a result of progression of AS, nonfatal myocardial infarction, coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), hospitalisation for unstable angina, and nonhaemorrhagic stroke. The key secondary endpoints were composites of subsets of the primary endpoint event categories.</p><p style="margin-left:10.0pt; margin-right:71.9pt; text-align:justify">Compared to placebo, ezetimibe/simvastatin 10/40 mg did not significantly reduce the risk of MCE. The primary outcome occurred in 333 patients (35.3%) in the ezetimibe / simvastatin group and in 355 patients (38.2%) in the placebo group (hazard ratio in the ezetimibe / simvastatin group, 0.96; 95% confidence interval, 0.83 to 1.12; p = 0.59). Aortic valve replacement was performed in 267 patients (28.3%) in the ezetimibe / simvastatin group and in 278 patients (29.9%) in the placebo group (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; p = 0.97). Fewer patients had ischemic cardiovascular events in the ezetimibe / simvastatin group (n = 148) than in the placebo group (n = 187) (hazard ratio, 0.78; 95% CI, 0.63 to 0.97; p = 0.02), mainly because of the smaller number of patients who underwent coronary artery bypass grafting.</p><p style="margin-left:10.0pt; margin-right:71.8pt; text-align:justify">Cancer occurred more frequently in the ezetimibe / simvastatin group (105 versus 70, p = 0.01). The clinical relevance of this observation is uncertain as in the bigger SHARP trial the total number of patients with any incident cancer (438 in the ezetimibe/ simvastatin versus 439 placebo group) did not differ. In addition, in the IMPROVE-IT trial the total number of patients with any new malignancy (853 in the ezetimibe/simvastatin group versus 863 in the simvastatin group) did not differ significantly and therefore the finding of SEAS trial could not be confirmed by SHARP or IMPROVE-IT.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:10.0pt; margin-right:70.3pt; text-indent:-1.5pt">Absorption</p><p style="margin-left:10.0pt; margin-right:71.8pt">After oral administration, ezetimibe is rapidly absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). Mean maximum</p><p>&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:10.0pt; margin-right:71.85pt; text-align:justify">plasma concentrations (Cmax) occur within 1 to 2 hours for ezetimibe-glucuronide and 4 to 12 hours for ezetimibe. The absolute bioavailability of ezetimibe cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection.</p><p style="margin-left:10.0pt; margin-right:71.85pt; text-align:justify">Concomitant food administration (high fat or non-fat meals) had no effect on the oral bioavailability of ezetimibe when administered as Ezetimibe 10 mg tablets. Ezetimibe can be administered with or without food.</p><p>Distribution</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:71.95pt; text-align:justify">Ezetimibe and ezetimibe-glucuronide are bound 99.7% and 88 to 92% to human plasma proteins, respectively.</p><p>Biotransformation</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:10.0pt; margin-right:71.8pt; text-align:justify">Ezetimibe is metabolised primarily in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively. Both ezetimibe and ezetimibe- glucuronide are slowly eliminated from plasma with evidence of significant enterohepatic recycling. The half-life for ezetimibe and ezetimibe-glucuronide is approximately 22 hours.</p><p>Elimination</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:71.95pt; text-align:justify">Following oral administration of 14C-ezetimibe (20 mg) to human subjects, total ezetimibe accounted for approximately 93% of the total radioactivity in plasma. Approximately 78% and 11% of the administered radioactivity were recovered in the faeces and urine, respectively, over a 10-day collection period. After 48 hours, there were no detectable levels of radioactivity in the plasma.</p><p style="margin-left:10.0pt; margin-right:420.15pt">Special Populations Paediatric population</p><p style="margin-right:72.05pt; text-align:justify">The pharmacokinetics of ezetimibe are similar between children &ge; 6 years and adults. Pharmacokinetic data in the paediatric population &lt; 6 years of age are not available. Clinical</p><p>&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:10.0pt; margin-right:72.15pt; text-align:justify">experience in paediatric and adolescent patients includes patients with HoFH, HeFH, or sitosterolaemia.</p><p>Elderly</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:71.75pt; text-align:justify">Plasma concentrations for total ezetimibe are about 2-fold higher in the elderly (&ge; 65 years) than in the young (18 to 45 years). LDL-C reduction and safety profile are comparable between elderly and young subjects treated with Ezetimibe. Therefore, no dosage adjustment is necessary in the elderly.</p><p>Hepatic impairment</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:71.75pt; text-align:justify">After a single 10-mg dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic impairment (Child-Pugh score 5 or 6), compared to healthy subjects. In a 14-day, multiple-dose study (10 mg daily) in patients with moderate hepatic impairment (Child-Pugh score 7 to 9), the mean AUC for total ezetimibe was increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects. No dosage adjustment is necessary for patients with mild hepatic impairment. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe (Child-Pugh score</p><p style="margin-right:87.2pt">&gt; 9) hepatic impairment, Ezetimibe is not recommended in these patients (see section 4.4). Renal impairment</p><p>After a single 10-mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl</p><p style="margin-left:10.0pt; margin-right:71.8pt; text-align:justify">&le; 30 mL/min/1.73 m2), the mean AUC for total ezetimibe was increased approximately 1.5- fold, compared to healthy subjects (n = 9). This result is not considered clinically significant. No dosage adjustment is necessary for renally impaired patients.</p><p style="margin-left:10.0pt; margin-right:71.95pt; text-align:justify">An additional patient in this study (post-renal transplant and receiving multiple medications, including ciclosporin) had a 12-fold greater exposure to total ezetimibe.</p><p>Gender</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:72.05pt; text-align:justify">Plasma concentrations for total ezetimibe are slightly higher (approximately 20%) in women than in men. LDL-C reduction and safety profile are comparable between men and women treated with Ezetimibe. Therefore, no dosage adjustment is necessary on the basis of gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:10.0pt; margin-right:71.75pt; text-align:justify">Animal studies on the chronic toxicity of ezetimibe identified no target organs for toxic effects. In dogs treated for four weeks with ezetimibe (&ge; 0.03 mg/kg/day) the choles-terol concentration in the cystic bile was increased by a factor of 2.5 to 3.5. However, in a one-year study on dogs given doses of up to 300 mg/kg/day no increased inci-dence of cholelithiasis or other hepatobiliary effects were observed. The significance of these data for humans is not known. A lithogenic risk associated with the therapeutic use of Ezetimibe cannot be ruled out.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:71.9pt; text-align:justify">In co-administration studies with ezetimibe and statins the toxic effects observed were essentially those typically associated with statins. Some of the toxic effects were more pronounced than observed during treatment with statins alone. This is attributed to pharmacokinetic and pharmacodynamic interactions in co-administration therapy. No such interactions occurred in the clinical studies. Myopathies occurred in rats only after exposure to doses that were several times higher than the human therapeutic dose (approximately 20 times the AUC level for statins and 500 to 2000 times the AUC level for the active metabolites).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-right:71.85pt; text-align:justify">In a series of in vivo and in vitro assays ezetimibe, given alone or co-administered with statins, exhibited no genotoxic potential. Long-term carcinogenicity tests on ezetimibe were negative.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:10.0pt; margin-right:71.85pt; text-align:justify">Ezetimibe had no effect on the fertility of male or female rats, nor was it found to be teratogenic in rats or rabbits, nor did it affect prenatal or postnatal development. Ezetimibe crossed the placental barrier in pregnant rats and rabbits given multiple doses of 1000 mg/kg/day. The co- administration of ezetimibe and statins was not teratogenic in rats. In pregnant rabbits a small number of skeletal deformities (fused thoracic and caudal vertebrae, reduced number of caudal vertebrae) were observed. The co-administration of ezetimibe with lovastatin resulted in embryolethal effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:10.0pt; margin-right:394.85pt">Lactose Monohydrate Microcrystalline Cellulose Croscarmellose</p><p style="margin-right:438.8pt">Sodium Povidoe K29/32</p><p style="margin-right:405.15pt">Sodium Lauryl Sulphate Magnesium stearate Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:18.1pt">Do not store above 30 &deg;C.</p><p style="margin-left:18.1pt">Keep out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:22.8pt"><strong>Immediate Container: </strong>3X10&rsquo;s tablets packed in Alu &ndash; PVC/PVDC blister</p><p style="margin-left:22.8pt"><strong>Secondary Container: </strong>Carton with PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:22.0pt">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267 Jeddah 21442
Tel: +966-12-6081111
Fax: +966-12-6081222.
Kingdom of Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>